DOH Administrative Order 2019-0036 Establishment of F1 Plus BNB and BNBi Program

Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY
SEP 09 2019
ADMINISTRATIVE ORDER
No. 2019- D036
SUBJECT: Implementing Guidelines _on_ the Establishment of Fourmula One

Plus for Health Botika ng Bayan (F1 Plus BNB) And Fourmula One
Plus for Health Botika ng Bayani (F1 Plus BNBi) Program
I. RATIONALE
As mandated by the Constitution under Section 15, Article II, “The State shall protect
and promote the right to health of the people and instill health consciousness among them.”’,
Section 11, Article XIII stipulates that the State shall also adopt an “integrated and
comprehensive approach to health development which shall endeavor to make essential
goods, health and other social services available to all the people at affordable cost”.
Also, the Republic Act No. 9502 otherwise known as the Universally Accessible
Cheaper and Quality Medicines Act of 2008, mandates the State to protect public health and,
when public interest or circumstances so requires, to adopt appropriate measures to promote
and ensure access to affordable quality drugs and medicines for all.
The Department of Health (DOH) established the Botika ng Barangay (BnB) program
in 2004, which was successful in improving the access to medicines of previously deprived
areas. However, there remains a lot of communities without supply of medicines. During the
implementation of the BnB, the lack of competent personnel to supervise the management of
medicines persisted, causing the sustainability, efficiency and effectiveness of the medicines
to stagnate. The DOH then issued a moratorium in January 2011 on the establishment of
additional BnBs until such time that the system problems were addressed. Department
Memorandum No. 2013-0053 dated February 18, 2013 entitled “Moratorium on the
Establishment of Botika ng Barangay and its variants” was issued to phase out the program
primarily due to several BnBs operating without the Special License to Operate (SLTO), and
also because of lack of rationality in the distribution and range of services that the BnBs
provided. All existing BnBs with SLTO were encouraged to upgrade their Pharmacy services
by securing a License to Operate (LTO) either as a regular pharmacy or a Retail Outlet foras
Non-Prescription Drug (RONPD).
The Botika Ng Bayan (BNB) was launched by Philippine International Trading

Corporation (PITC) in September 2004 in partnership with the DOH and the Food and Drug
Administration (FDA). Its objective is to increase access to low-priced quality medicines and
serve as a distribution network for the Parallel Drug Imports (PDIs) which were being
brought in by the government.
To further improve the access to medicines while the BnB and BNB programs were in
a moratorium, the Department established the Medicines Access Program (MAPs), providing
free medicines to patients with breast cancer, childhood cancer, diabetes, hypertension and
af
Ayal’
i/
al
v
Building 1, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila © Trunk Line 651-7800 local 1108, 1111, 1112, 1113
Direct Line: (02) 711-9502, 711-9503 Fax: (02) 743-1829 « URL: http://www.doh.gov.ph; e-mail: ftduque@doh.gov.ph
ry
@
mental health illness. The drug availability in health facilities increased from 25% in 2009 to
59% in 2016 because of the implementation of the MAPs.
In line with the policy of Republic Act (RA) No. 11223, otherwise known as the
Universal Health Care Act of 2019, the national government shall support Local Government
Units (LGUs) in the financing of capital investment and provision of population-based
interventions. The national government recognizes the importance of access to medicines as
part of the fundamental human right to health and the socio-economic agenda to achieve
Universal Health Care (UHC). Pursuant to AO No. 2018-0014, the DOH aims
goals outlined in the
toattain the
Philippine Development Plan 2017-2022 and build on the concept of
FOURmula One Plus for Health through the expansion of the four pillars of health reforms
and highlighting greater focus on performance accountability towards the Filipino people.
Cognizant of these issues on access to medicines, the Government pledged to revitalize

the “Botika Ng Bayan” using government instruments such as pooled procurement, parallel
drug importation and price-volume direct negotiation with pharmaceutical manufacturers for
single-source essential medicines. To address gaps observed
program, the DOH shall
inthe past implementation of the
ensure a holistic, whole-of-systems approach in the implementation
of improving the supply chain management integration with other health and social services
of the national government and institutionalizing good pharmacy practice to improve the
quality of services.
Il. OBJECTIVES
1. To ensure accessto safe, effective and quality medicines to patients, prioritizing
the marginalized, underserved population, vulnerable populations (Persons with
Disabilities (PWDs), elderlies, children, indigenous populations (IP), those living
in Geographically Isolated and Disadvantaged Areas (GIDAs) and Urban Poor
Areas), active uniformed personnel and their dependents;
2. To reduce out-of-pocket expenses by providing free essential medicines to health

facilities catering specially to underserved population;
3. To establish partnerships with Local Chief Executives (LCEs), Medical Center

Chief of Uniformed Personnel, hospitals and other government agencies in
implementing the F1 Plus BNB and F1 Plus BNBi program.
Ill. SCOPE AND COVERAGE
This Order shall apply to all priority government health facilities including but not
limited to Rural Health Units (RHUs), Health Centers (HCs), Government Hospitals,
National and Local Government Centers and Bangsamoro Autonomous Region in Muslim
Mindanao (BARRM) health facilities with medical assistance programs to be called as
FOURmula One Plus Botika Ng Bayan (F1 Plus BNB) as
well as Philippine National Police
(PNP) and Armed Forces of the Philippines Military Treatment Facilities (AFPMTF) as
FOURmula One Plus Botika Ng Bayani (F1 Plus BNBi).
IV. DEFINITION OF TERMS
1. FOURmula One Plus Botika Ng Bayan (F1 Plus BNB) — Pharmacy outlets in
Rural Health Units, Health Centers, Government Hospitals, National and Local
Government Centers and Bangsamoro Autonomous Region in Muslim Mindanao
(BARMM) health facilities with Medical Assistance Program where the medicine
yh
supplies are funded by the Department of Health (DOH)
all priority patients.
to be provided for free to
FOURmula One Plus Botika Ng Bayani (F1 Plus BNBi) — Pharmacy outlets in
the Philippine National Police (PNP) and Armed Forces of the Philippines
Military Treatment Facilities (AFPMTF) where the medicines supplies are funded
by the Department of Health (DOH) to be provided for free to all uniformed
personnel and their dependents.
Geographically Isolated and Disadvantaged Areas (GIDA) - are communities

with marginalized populations, physically and socio-economically separated from
mainstream society such as island municipalities, up-land communities, hard-to-
reach areas, and conflict areas or zones.
Good Pharmacy Practice (GPP) - is the practice of pharmacy provided under

R.A. No. 10918 or the Philippine Pharmacy Act, that responds to the needs of the
people who use the pharmacists’ services to provide optimal, evidence-based
care.
National Drug Policy Compliance Officer (NDPCO) — Pharmacists under the

DOH-Centers for Health Development (CHD) or
Ministry of Health- Bangsamoro
Autonomous Region in Muslim Mindanao (MOH-BARRM) with a Plantilla
position that are designated to oversee the implementation of all programs and
activities of the Pharmaceutical Division and other tasks as indicated in the
'
Department Memorandum No. 2016-0081.
Near Expiry Medicines — refers to the medicines that is six (6) months prior to
expiration date.
Ordering Agreement — refers to a written agreement in the nature of an option
contract between the procuring entity and the Lowest Calculated and Responsive
Bidder granting the procuring entity the option to either place an order for any of
the goods identified in the Order Agreement List or not buy at all, within a given
period of time.
Order Agreement List - refers to the list of goods, and their corresponding
technical specifications, projected quantities, and fixed prices, subject of the
Ordering Agreement.
Pharmacovigilance - as the science and activities relating to detection,

assessment, understanding and prevention of adverse effects or any other drug-
related problem.
10. Philippine Pharma Procurement, Inc. (PPP) — formerly known as PITC

Pharma Inc. (PPI), is a subsidiary of the Philippine International Trading
Corporation (PITC) and an affiliate of the National Development Company
(NDC). It is the only pharmaceutical government owned and controlled
corporation (GOCC) tasked to provide the low-priced quality ensured medicines
to the Filipino people and establish a common facility for pooled procurement that
can be accessed by government entities and other facilities undertaking
government programs
if deemed necessary.
as well as to undertake importation of medicines when and
4
iB
A
11. Public Health Pharmacist (PHP) — are Pharmacists hired under the Human
Resources for Health (HRH) of the DOH that are deployed to the different
provincial DOH offices nationwide. They are tasked to provide technical
assistance to primary healthcare facilities in terms of pharmaceutical supply chain
management (PSCM), and rational use of medicines.
12. Technical Assistant (TA) — DOH personnel assigned to monitor the supply and
inventory of pharmaceutical products in the dispensary or pharmacy under the
supervision of a licensed Pharmacist.
V. GENERAL GUIDELINES
1. All priority government health facilities including but not limited to RHUs, HCs,
Government Hospitals, National and Local Government Centers and Bangsamoro
Autonomous Region in Muslim Mindanao (BARRM) health facilities with
medical assistance program shall be called as F1 Plus BNB. This BNB outlet shall
make available essential medicines to patients prioritizing, the marginalized,
underserved population, and vulnerable populations (PWDs, elderlies, children,
indigenous populations (IP), those living in Geographically Isolated and
Disadvantaged Areas (GIDAs) and Urban Poor Areas).
The PNP and the AFPMTF shall have dispensaries or pharmacies that will provide
free access to essential medicines to be called as F1 Plus BNBi. This pharmacy
shall make available essential medicines for active uniformed personnel and their
dependents.
The DOH shall pool

requests for essential medicines and procure said medicines
either through the Central Office Bids and Award Committee (COBAC) of the
DOH
or through Agency-to-Agency mode of procurement with the PPPI to ensure
adequate supply of essential medicines for the program in the public sector, using
the instruments provided in R.A. No. 9502, such as competitive bidding,
importation and when necessary the use of Trade-Related Aspects of Intellectual
Property Rights (TRIPS) flexibilities for exorbitantly priced drugs which address
priority diseases.
The DOH CHDs and Ministry of Health (MOH)-BARMM together with the Local
Government Units (LGUs), Philippine National Police (PNP) and Armed Forces
of the Philippines (AFP) shall prepare a specific and separate Memorandum of
Agreement (MOA) for the joint implementation of the program (Annex A-3),
The DOH, LGU, PNP and AFP shall work together in ensuring good governance
mechanisms and local accountability in the management of F1 Plus BNB and F1
Plus BNBi outlets in all prioritized government health facilities by complying
with FDA regulatory requirements and other standards contained in relevant
existing laws.
The DOH - Pharmaceutical Division (PD), through the CHDs and MOH-
BARMM shall jointly conduct capacity building activities and training to the F1
Plus BNB and F1 Plus BNBi personnel and provide orientation on the program
implementation. All F1 Plus BNB and F1 Plus BNBi outlets shall be offered with
a package of technical assistance such as Antimicrobial Stewardship (AMS) for
primary care, rational use of medicines, supply chain management, medicine
information system and drug pricing. .
lgv.
7. For far flung areas, the F1 Plus BNBoutlets through their TAs, shall regularly join
the community outreach of RHUs to bring needed medicines for patients that have
been profiled in the health facilities.
8. All Fl Plus BNBi outlets nationwide shall operate only within their jurisdiction
and bound toserve in their respective catchment areas as prescribed by the DOH
and monitored by FDA.
9. Only those suppliers listed in the Philippine Government Electronic Procurement

Systems (PhilGEPS) may participate as program suppliers for stock replenishment
on medicines.
10. No medicines procured under this program shall be sold to patients, to the access
sites, pharmacies or other drug establishments. The product shall bear a marking:
“Philippine Government Property-Department of Health NOT FOR SALE”
VI. SPECIFIC GUIDELINES
A. F1 Plus BNB and F1 Plus BNBi Outlet Nomination and Licensing
1. The DOH
support
shall
through
partner with the LGUs, regional PNP and AFP
technical assistance in pharmaceutical supply
in the provision of
chain management,
pharmacy operations and good pharmacy practice in F1 Plus BNB and F1 Plus
BNBi outlets that shall ensure the effective implementation of this program.
Creation of a functional committee for coordination and monitoring shall be
clearly identified and established.
The DOH CHDs and MOH- BARMM shall conduct a preliminary assessment of
all health facilities regarding their readiness to operate a F1 Plus BNB or F1 Plus
BNBi outlets using the Readiness Assessment Checklist (Annex B).
The LCE orthe head of agency shall submit to the DOH CHD or MOH-BARMM
a letter of intent (Annex C) to operate F1 Plus BNB orF1 Plus BNBi outlet to be
submitted to the DOH Central Office for approval and budgeting.
All nominated F1 Plus BNB and F1 Plus BNBi facilities shall comply with the
existing licensing guidelines of the FDA and Implementing Rules and
Regulations (IRR) of Republic Act No. 10918:
a. Secure a License to Operate (LTO):
i. For to
1 3" class municipalities (Category A), there must be a licensed
Pharmacist in each health facility who may be allowed to simultaneously
work and successively render pharmacy services in establishment/outlets
in 4 to 6" class municipalities (Category B). Under this provision,
simultaneous work means that a pharmacist can be employed in multiple
establishments/outlets, provided that there is no overlap in working time.
A pharmacist shall be allowed to supervise a maximum of four (4)
establishments/outlets classified under Category B.
yc pw
f°
FA
li. For Category B, a certified Technical Education and Skills Development
Authority (TESDA) National Certificate (NC)- III TAs shall be present
in establishments/outlets. The licensed pharmacists in Category B shall
comply with the following:
1. Shall be physically present in the establishment/outlet

for a minimum of two (2) hours a week;
2. Location of each establishment/outlet which the
licensed pharmacist supervises shall be within the same
province per region. However, the National Capital
Region (NCR), shall be considered as a single unit;
3. The distance between the two farthest
establishments/outlets supervised by a single licensed
pharmacist shall not exceed twenty-five (25) kilometers
(km) in distance;
4, Shall be allowed to supervise a maximum of fifteen (15)
establishments/outlets; and
5. The supervising pharmacist shall likewise comply with
the other relevant requirement as may be prescribed by
the Pharmacy Board in coordination with the FDA.
b. Submit a Sangguniang Bayan resolution or municipal ordinance stating the

establishment of the F1 Plus BNB outlet indicating its name and address.
c. The LGU shall submit a Risk Management Plan (RMP) of the proposed F1
Plus BNB outlet.
d. The LGU
shall pay a registration fee as prescribed by the FDA. The initial
registration shall be valid for two (2) years, and shall be renewable every
three (3) years thereafter.
e. The LGU
shall ensure that all
requirements as specified by the FDA are
completed prior to submission through the electronic portal, as per FDA
Circular No. 2016-004, to
facilitate the processing of LTO.
f. The DOH CHDs and MOH-BARMM shall assist the LGUs in processing the
LTO. .
B.F1 Plus BNB and F1 Plus BNBi Outlet Activation
1. A Memorandum of Agreement (MOA) shall be executed between DOH CHDs,

MOH-BARMM, LGUs, PNP or Department of National Defense (DND) for
AFP, which shall stipulate the roles and responsibilities of each party in the joint
implementation of the program.
2. The DOH CHDs and MOH-BARMM shall

provide a package of selected
essential medicines based on the F1 Plus BNB program product portfolio and
technical assistance to the target health facility to enhance their Pharmacy
services.
6
3. All DOH and LGU procured medicines shall be placed inside the F1 Plus BNB
outlets. Buffer stocks shall be placed inside a designated storage room in the
respective City Health Office (CHO) or Provincial Department of Health Office
(PDOHO) or MOH-BARMM warehouse for
rational management.
C. Operations
1. The LGU
-
hired Pharmacist for Category A and certified (TESDA NC-IID TAs,
as supervised by a Pharmacist in Category B, shall be responsible for ensuring
that the Fl Plus BNB outlet is compliant to regulatory requirements, Good
Distribution and Storage Practice (GDSP) and Good Pharmacy Practice (GPP)
standards.
a. The F1 Plus BNB and F1 Plus BNBi shall be expected to provide quality
Pharmacy services such as:
i. facilities and premises management;

ii. medicines supply management;
iii. dispensing of medicines and patient counselling;
iv. public health and pharmacy services such as, but not limited to:
a. Patient profiling
b. Pharmacovigilance
c. Drug therapy review; and
v. administrative and general services
b. The NDPCOs and PHPs shall provide supportive supervision, monitoring and
evaluation during operations of the F1 Plus BNB and F1 Plus BNBi outlets in
accordance with DOH standards. And shall report to the DOH
Pharmaceutical Division (PD).
D. Selection, Quantification and Forecasting of Medicines
1. Medicines to be included in the F1 Plus BNB or F1 Plus BNBi program shall be

in accordance with Republic Act No. 9502 or the Cheaper Medicines Act which
mandates the use of the latest edition of Philippine National Formulary (PNF) as
procurement basis for government agencies.
2. The DOH
shall selectmedicines based on the following criteria:
i, Morbidity report;
ii. Hospital admission report or Identification treatment record;
ili. Identified priority disease;
iv. Commonly needed medicines; and
v. Submitted end-user’s Requisition and Issuance Slip (RIS) — (Annex D)
3. The DOH
shall issue a
Department Memorandum for
the quarterly replenishment
of stocks through the submitted RIS based on ‘their actual consumption and
capacity to store medicines.
4. Medicines that are annually provided by the DOH nationwide or to selected

disease- endemic areas shall not be procured unless deemed necessary.
if
5. For budgeting purposes, the DOH shall collect every March, the requests for
medicines for the succeeding year.
E. Patient Eligibility
1. The eligible patient shall complete and sign the consent form (Annex E) which
will be filed and recorded in the patient registry by the establishment/outlet.
2. All patients with a valid prescription from a physician or AFPMTFs/ PNP

Medical Officer may avail of the prescribed medicines, if available, from F1 Plus
BNB
or F1 Plus BNBi outlets.
3. Medicines shall be dispensed to patients in complete treatment regimens for

antibiotics and one (1) month supply for maintenance medications.
F.Sourcing and Procurement

1. The acquisition of medicines shall be performed by PPPI through Agency-to-
Agency mode of procurement in accordance with R.A. No. 9184 or the
Government Procurement Reform Act.
2. A centralized ordering agreement shall be used as deemed necessary to assure

uninterrupted pharmacy services of the F1 Plus BNB and F1 Plus BNBi outlets.
3. If drug products are not locally available or with limited supply, parallel
importation and/or other TRIPs flexibilities shall be undertaken to ensure
continuous access for essential medicines in the F1 Plus BNB and F1 Plus BNBi
outlets.
G. Logistics Management
1. All Fl Plus BNB and

F1 Plus BNBi outlets shall manage their logistics according
to the standard procedures set by the DOH on pharmaceutical supply chain
management.
2. The procured medicines shall be directly delivered to the Fl Plus BNB and F1
Plus BNBi outlets through PPPI or an outsourced shipping agency.
3. All Fl Plus BNB and F1 Plus BNBi outlets shall be compliant with Good
Distribution and Storage Practice (GDSP) in accordance with the standards
adopted by the FDA.
4. To ensure uninterrupted supply of medicines for all Fl Plus BNB and F1 Plus
BNBi outlets, twenty percent (20%) of the total requested quantity of all the
outlets in the province, shall serve as the buffer stock which shall be maintained
at concerned PDOHO or MOH-BARMM.
H. Financing
1. The DOH shall ensure sufficient and available funds for the procurement of the
/isA
essential medicines and support to operations of the F1 Plus BNB and F1 Plus
BNBi outlets.
2. The LGU, PNP and AFP shall continue to allocate funds for medicines that are
not being supplied in the F1 Plus BNB and F1 Plus BNBi program as
part their
of
responsibility to provide health services to their constituents.
I. Rational Use of Medicines and Quality Assurance
L. Only essential medicines shall be rationally selected and procured at the national
level and distributed to all identified health facilities. GDSP and other conditions
reflected on the label of drug products shall be adhered to at all times by the
Pharmacist and Technical Assistant (TA) in charge of the Fl Plus BNB or F1
Plus BNBi outlet.
The designated Pharmacist and TA shall offer full pharmacy services to F1 Plus
BNB
and F1 Plus BNBi clients including patient counseling on medicines use.
The quantity of medicines to be dispensed by the Fl Plus BNB and F1 Plus BNBi
outlets shall be in accordance with the prescribed therapeutic regimen to a single
patient.
No F1 Plus BNB and F1 Plus BNBi drug product shall be sold or find their way
in the trade through retail and pilferage. Civil, criminal, and administrative
sanctions, as may be proper, shall be imposed following existing government
policies.
The medicines delivered to the health facilities shall be subject to random FDA
post-marketing surveillance protocols.
Near expiry medicines (within six (6) months prior to expiry date) shall be
reported to the nearest CHDs or MOH-BARMM, while expired medicines shall
be disposed of in accordance with the Joint Department of Environment and
Natural Resources (DENR)- Department of Health (DOH) Administrative Order
No. 02, series of 2005. A witness from DOH-CHD or MOH-BARMM, FDA and
COA
shall be present whenever disposal of expired drugs is conducted.
VII. ROLES AND RESPONSIBILITES
A. Department of Health (DOH)
1. Pharmaceutical Division (DOH-PD)
i. DOH,
as the lead agency in the health sector shall provide the overall
and guidelines in the implementation of the F1 Plus
policy framework
BNB
and F1 Plus BNBi program in coordination with CHDs, MOH-
BARMM, PNP and AFP for effective local implementation.
ii. The DOH-PD through the CHDs and MOH-BARMM shall

regularly
conduct monitoring activities of all F1 Plus BNB and F1 Plus BNBi
outlets nationwide to maintain compliance to the program standard and
FDA regulation.
iii. The DOH-PD shall supervise the implementation of the F1 Plus BNB
and F1 Plus BNBi program including its funding for medicines,
logistics and human resources.
iv. The DOH-PD shall develop policies and implementation guidelines

including manual of procedures for F1 Plus BNB and F1 Plus BNBi
outlets.
v. The DOH-PD shall lead the implementation of pharmacy practice

standards and requirements for the F1 Plus BNB and F1 Plus BNBi.
vi. The DOH-PD shall conduct random supervisory monitoring using a

harmonized tool (Annex F) to analyze the implementation and
compliance to the F1 Plus BNB and F1 Plus BNBi outlet standards.
vii. The DOH-PD shall provide technical assistance to the regional

counterpart on the matters affecting F1 Plus BNB and F1 Plus BNBi
operations.
viii. The DOH shall employ additional PHPs and TAs to augment the
shortage of medicine management experts in local health facilities for
the first three (3) years of the implementation of the program.
. Procurement and Supply Chain Management Team (PSCMT)
i. Provide technical assistance on the supply chain management of F1

Plus BNB and F1 Plus BNBi commodities
. Central Office Bids and Awards Committee (COBAC) with the Procurement
Service (PS)
i. The DOH-COBAC shall consolidate the Project Procurement

Management Plan (PPMP) as part of the DOH Annual Procurement
Plan (APP).
. Disease Prevention and Control Bureau (DPCB)
i. The DOH Health Program Managers shall facilitate the inclusion of

program medicines into the F1 Plus BNB and F1 Plus BNBi program
and define recommended monitoring parameters.
. Centers for Health Development (CHD) and Ministry of Health-

Bangsamoro Autonomous Region of Muslim Mindanao (MOH-BARMM)
i. The CHD and MOH-BARMM shall oversee the implementation of the

F1 Plus BNB and F1 Plus BNBi program at the DOH level.
ii. The CHD and MOH-BARMM through the Development Management
Officers (DMOs) shail coordinate with the National Drug Compliance
Policy Officer (NDCPO) designate in the F1 Plus BNB and F1 Plus
BNBi for the nomination and activation of a target outlet.
Ay
iiii The CHD and MOH-BARMM shall manage buffer stocks in
PDOHO/CHD or MOH-BARMM warehouse and distribution of F1
Plus BNB or
F1 Plus BNBi commodities.
iv. The CHD and MOH-BARMM through the NDPCO designates shall
manage PHPs and TAs hired through the Human Resources for Health
(HRH) Deployment Program.
v. The CHD Directors and MOH-BARMM Minister of Health through

the NDPCO designates shall collect, consolidate and analyze the
reports coming from the Fl Plus BNB and F1 Plus BNBi outlets on a
monthly basis.
vi. The CHD and MOH-BARMM shall submit monthly monitoring

reports to DOH-PD on the status of the program implementation.
vii. The CHD and MOH-BARMM shall

allot augmentation fund for the
advocacy, training, monitoring and evaluation of F1 Plus BNBand F1
Plus BNBi Program.
viii. The CHD Director and MOH-BARMM Minister of Health and their
staff shall and resolve regional issues and other concerns needing
actions on the operations of the program.
ix. The CHD and MOH-BARMM shallenforce diligently the mechanism

of stock transfer of medicines among RHUs, HCs and Military
Hospitals to prevent wastage in coordination with the LGUs using the
prescribed form (Annex G). This shall be properly coordinated with the
assigned PHP and TA as well as the regional program manager.
x. The TAs shall oversee and manage the operations of F1 Plus BNB or
Fl Plus BNBi outlets in their facilities, account for and record the
movement of the stocks and provide the medicines for free to priority
patients. They shall submit necessary reports to the DOH CHD and
MOH-BARMM on
time through the PHPs.
xi. The TAs shall join the regular community outreach activities and
dispense medicines in the Fl Plus BNB satellite outlets in the
barangays for patient that have been profiled in the RHUs.
B.Local Government Unit (LGU), Philippine National Police (PNP) and Armed
Forces of the Philippines Military Treatment Facilities (AFPMTF):
1. The LGUs shall hire their own Pharmacists and TAs to manage the F1 Plus BNB
outlet as the DOH shall only temporarily provide the necessary human resource
needed for the implementation of the program for the first three years.
The LGU, PNP orAFP shall ensure proper implementation of the F1 Plus BNB or
Fl Plus BNBi Program in its area of jurisdiction in coordination with the CHDs
and MOH-BARMM, keep and maintain prompt inventory of drug supplies and
educate the communities on rational use of medicines.
The LGU, PNP and AFP shall obligate the BNB Pharmacist to have a complete
inventory, record keeping, reporting of consumption and medication needs of the
community to ensure responsive medications list.
The LGU, PNP and AFP shall allow the DOH-assigned PHP to conduct
monitoring, inspection or audit of the Fl Plus BNB or F1 Plus BNBi outlet as
part of program evaluation.
The LGU, PNP and AFP shall be responsible for improving the F1 Plus BNB or
Fl Plus BNBi Outlets by mobilizing budget for the enhancement of
pharmaceutical standards and minimum facility requirements and likewise
observe the GDSP in accordance with FDA guidelines.
The LGU shall apply for a LTO for each F1 Plus BNB outlet including continuing
renewalof license every three (3) years.
The PNP and APFMITF shall ensure that the pharmacy has a LTO from
FDA/DOH.
The LGU, PNP and AFP shall collaborate with CHD or MOH-BARMM to
integrate health services that are aligned to the Service Delivery Network (SDN).
The LGU, PNP and AFP shall assist the DOH in the promotion and advocacy of
the F1 Plus BNB and F1 Plus BNBi program for better implementation and
utilization of the program.
10. The designated PHPs and TAs in the F1 Plus BNB or F1 Plus BNBi outlets shall
be allowed to conduct full pharmacy services to their clients including patient
profiling, gathering and filing consent forms from patient, and counseling during
medicines dispensing.
11. The CHO, Medical Health Officer (MHO) or the Chief Pharmacist of AFPMT
and PNP hospitals shall ensure efficient and effective implementation of the
program.
12. The CHO, MHO

or the Chief Pharmacist shall determine the quantity needed by
the population in the catchment area of the health facility using the quantification
tool or the RIS. This document shall be forwarded to the assigned PHP.
13. The CHO,

the
MHO
or the Chief Pharmacist through their Pharmacist or TA shall
ensure following:
i. proper storage and warehousing of the commodities;
ii. coordination of slow moving and inventories to the CHD and MOH-
BARMM;
iii. submission of monthly reports on the utilization inventory including
patient registry to the CHD and MOH-BARMM; and
iv. coordination with the CHD and MOH-BARMM on issues and
concerns regarding the program.
C. Food and Drug Administration (FDA)
1. The FDA shall define regulatory requirements and facilitate licensing of F1 Plus
BNBand F1 Plus BNBi outlets.
2. The FDAshall enforce policies on the regulation standards of the F1 Plus BNB
and F1 Plus BNBi outlets and monitor compliance of F1 Plus BNB and F1 Plus
BNBi requirements.
3. The FDA shall ensure the safety, efficacy and quality of drug products being
procured and prioritize the release of regulatory documents such as, but not
limited to laboratory analysis and Certificate of Product Registration (CPR).
4. The FDA shall conduct post-marketing surveillance of all F1 Plus BNB and F1
Plus BNBi medicines.
D. Philippine Pharma Procurement, Inc. (PPP])
1. Subject to the agreement with DOH, PPPI shall provide procurement service to
F1 Plus BNB and F1 Plus BNBi program in accordance with the Philippine
Procurement Law.
2. The PPPI shall procure the F1 Plus BNB and F1 Plus BNBi medicine at the most
reasonable cost (quote prices that are fixed for a period of (6) six months).
3. The PPPI shall ensure continuous supply of medicines that shall be included in
the F1 Plus BNB and F1 Plus BNBi program.
4. The PPPI shall coordinate with DOH-PD regarding problems encountered on

medicines management while under their case.
VII. PROGRAM MONITORING AND EVALUATION
A. The DOH and its CHDs and MOH-BARMM shall be the lead units in monitoring
the performance of all F1 Plus BNB and F1 Plus BNBi outlets and shall have the
authority to check on their inventory records notwithstanding and without prejudice
to a similar role that the LGU and hospital proponents may undertake or to the
regulatory functions of the FDA.
B. The Fl Plus BNB and F1 Plus BNBi outlets shall maintain the integrity and
transparency of their records and shall be made available whenever asked by the
CHD or MOH-BARMM concerned, the DOH and other regulatory units.
C. Reports on monitoring shall be submitted by the F1 Plus BNB and F1 Plus BNBi
outlets to their respective CHDs and MOH-BARMM
on
a monthly basis, and shall
be forwarded to the DOH- Health Regulation Team (HRT) -PD.
D. During implementation, a yearly evaluation of the program shall be conducted by

the PD. Three (3) years after implementation, the program shall undergo review in
order to determine whether the same shall be continued or terminated.
UF ihe
IX. COORDINATING INSTRUCTIONS
A. The CHD Director and MOH-BARMM Minister of Health shail have the overall
responsibility on the implementation of the F1 Plus BNB and F1 Plus BNBi program
and shall be supported by the DOH-PD by determining recommendations for
improvement in
the operation of the outlets with the assurance that provisions of this
guideline shall be complied with.
B. Policy issues shall be referred to the DOH-PD for final clearance and approval.
C. The FDA Director General shall assist the CHD Directors, MOH-BARMM Minister
of Health and the PD, by assigning Food-Drug Regulation Officer (FDRO) in their
respective areas of jurisdiction and provide technical assistance and expert opinion
as may be required in the establishment of F1 Plus BNB and F1 Plus BNBi outlets.
D. The Fl Plus BNB and F1 Plus BNBi outlets are required to submit monthly
utilization, inventory reports and patient registry to DOH-CHD, MOH-BARMM and
DOH-CO
as
part of the program review, and accounting and auditing procedures
using electronic forms provided in a software being implemented by the PD. For
outlets with no access to the Internet, printed forms shall be used, to be collected by
the DOH CHDs and MOH-BARMM through their PHPs. The PHPs shall be
responsible for uploading the data collected at the outlets without access to internet.
E. All inventory data as well as the RIS of all F1 Plus BNB and F1 Plus BNBi outlets
shall be quarterly collated by PHPs and submitted to their respective CHDs and
MOH-BARMM
to be forwarded to the DOH-PD forreplenishment of
stocks.
F, The CHD Directors and MOH —-BARMM Minister shall authorize their PHPs to
serve as the Supervising Pharmacist of their respective F1 Plus BNB and F1 Plus
BNBi outlets and conduct monitoring and validation.
G. The LGUs, PNP and AFP having the primary responsibilities for the health needs of
their constituents, shall perform the following acts which shall be stipulated in a
MOA between the LGU, PNP, AFP and the CHDs/ MOH-BARMM, accordingly:
1. Allot required outlets, computer, internet connection, ventilation and logistics for
the operation of the F1 Plus BNB outlets and F1 Plus BNBi
2. Provide a Pharmacist or TA; and
3. Submit mandatory monthly inventory reports (Annex H) and patient registries to
their respective CHDs and MOH-BARMM
X. REPEALING CLAUSE
Previous issuances, or any of their provisions, which are inconsistent with or contrary
to the provisions of this Administrative Order, including AO No. 144, AO No. 34, AO No.
64, AO No. 70, and AO No. 159, are hereby modified or repealed accordingly. All other
issuances which are not affected by this Administrative Order, shall remain valid and in
effect.
XI. SEPARABILITY CLAUSE
In case any provision of this Order, or the application thereof, is declared

unconstitutional or rendered invalid, other portions not affected thereby shall remain in full
force and effect.
XII. EFFECTIVITY
This Order shall take effect immediately after its publication in the Official Gazette.
SCO T/DUQUE
II,
Secretary of Health
MD, MSc.
15
ANNEX A-1
(MOA BETWEEN DOH AND LGU)
MEMORANDUM OF AGREEMENT
KNOW ALL MEN BY THESE PRESENTS:
This Memorandum of Agreement (MOA) executed on the day of

2019 in by and between:
The DEPARTMENT OF HEALTH (DOH),

anational government agency and existing
under the laws of the Republic of the Philippines with principal office at
, represented by » in
her capacity as Director/ Minister of Health, DOH Center for Health Development
(CHD) Ministry of Health — Autonomous Region of Muslim Mindanao (MOH-BARMM)
hereinafter referred to as “DOH”.
-and-
CITY OF as defined in the 1991 Local Government Code of the Philippines,

with office address at (Address of LGU) represented herein by the (Name of LCE), City
Mayor pursuant to Sangguniang Bayan/Panlalawigan Resolution No.
to as “LGU”. _
and herein referred
WITNESSETH, that
WHEREAS, the 1987 Constitution of the Philippines mandates that the State shall protect
and promote the right to health of the Filipino people and instill health consciousness
among them;
WHEREAS, under Section 11, Article XIII of the Constitution, the State shall adopt an
integrated and comprehensive approach to health development which shall endeavor to
make essential goods, health and other social services available to all the people at
affordable cost;
WHEREAS, RA No. 9502, otherwise known as the Universally Accessible Quality and
Cheaper Medicines Act of 2008, mandates the Department of Health (DOH)
access to essential medicines for the country’s priority diseases;
to
increase
WHEREAS, RA No. 6675 (Generics Act of 1988) prescribes further that it is the policy
of the State to ensure the adequate supply of drugs and medicines with generic names and
at the lowest possible costs;
WHEREAS, the Local Government Units are mandated by RA No. 7160 (Local
Government Code of 1991) to implement various health programs, projects and initiatives
to ensure that the people will be provided with basic health services; purchase of medicines,
medical supplies, and equipment needed to carry out the services herein
WHEREAS, Government Hospitals and Rural Health Units are among of the health
facilities in the Local Government Units which can be accessed by the community for low-
priced quality medicines;
WHEREAS, pursuant to the national program, President Rodrigo Roa Duterte pledged to
provide funds for government health programs specifically on the availability of medicines
under the new Philippine Health Agenda (PHA);
WHEREAS, to bridge the gap on access to medicines and to improve the current systems
in the pharmaceutical market, the revitalization and remodeling of the “Botika ng Bayan”
1
shall be adopted using government instruments such as pooled procurement, parallel drug
importation, and price-volume direct negotiation with pharmaceutical manufacturers for
single-source essential medicines;
WHEREAS, the establishment of the “FOURmula 1 Plus BOTIKA NG BAYAN (F1

Plus BNB)” in Rural Health Units (RHUs), Health Centers (HCs), Bangsamoro
Autonomous Region in Muslim Mindanao (BARRM) health facilities, Military Hospitals
- Philippine National Police (PNP) and Armed Forces of the Philippines (AFP) health
facilities or at the point of care shall avoid additional expenses for the patient and shall
address the other health-related issues such as cost-effectiveness of treatment,
antimicrobial resistance and adverse drug events;
WHEREAS, the national government aims to ensure access to safe, effective and quality
medicines to patients, prioritizing the marginalized, underserved population, vulnerable
populations (Persons with Disabilities (PWDs), elderlies, children, indigenous populations
(IP), those living in Geographically Isolated and Depressed Areas (GIDAs) and Urban Poor
Areas);
WHEREAS, increasing government subsidy for essential medicines, for the benefit of the
poor and vulnerable population, shall reduce the patients’ high out-of-pocket (OOP)
spending on medicines, including those covered by the No-Balance Billing (NBB)
program, by preventing frequent stock outs of medicines in government health facilities;
WHEREAS, the F1 Plus BNB program shall ensure the strict enforcement of good
pharmacy practice in all levels of health care;
~and-
WHEREAS, the DOH is now implementing a free medicines access program for
vulnerable and special populations affected by diseases which cause a significant health
and economic burden in the country;
NOW THEREFORE, for and in consideration of the foregoing, the parties hereto have
agreed that the following terms and conditions shall be observed/implemented:
ARTICLE I
DOH AND LOCAL GOVERNMENT EXECUTIVE OFFICES GUIDELINES FOR
I
THE PROCESSING AND DELIVERY OF MEDICINES FOR THE DOH
FOURMULA PLUS BOTIKA NG BAYAN
THE UNIVERSAL HEALTH CARE THRUST
(F1
PLUS BNB) PROGRAM UNDER
1. GENERAL GUIDELINES
1.1. The LGU, through HCs, shall work with the Department of Health (DOH) in
determining the drug needs concerning the specifications, quantities and
allocation of essential medicines in accordance with Executive Order No. 49,
mandating the use of the latest edition of Philippine National Formulary as
procurement basis for government procurement agencies.
1.2. This program shall provide essential medicines to the health facilities free of
charge. Other routine care costs (i.e. laboratory tests, diagnostic exams) not
included by the program shall be covered by PhilHealth reimbursements (for
eligible members) and/or referred to foundations and other funding
institutions.
1.3. All government health facilities shall have pharmacies/dispensaries providing

free access to essential medicines, which shall be called as DOH
2
FOURMULA Plus BOTIKA NG BAYAN
1!
(F1 Plus BNB). The F1 Plus

BNB outlet shall make available essential medicines to poor and vulnerable
patients, including persons with disability, the elderly, women and children.
1.4. The DOH, as

the leader in the health sector shall provide the overall policy
framework and guidelines in the implementation of the F1 Plus BNB
Program, working with its Centers of Health Development (CHDs) and
Ministry of Health- Bangsamoro Autonomous Region in Muslim Mindanao
(MOH-BARRM) for effective local implementation.
1.5. The DOH and the LGUs shall work together in ensuring good governance
mechanisms and local accountability in the management of F1 Plus BNB in
all government health facilities through compliance with Food and Drug
Administration (FDA) regulatory requirements and DOH standards on good
supply chain management.
|
1.6. The DOH CHD and MOH-BARMM shall

initiate partnerships with LGUs
and will provide support through technical assistance in supply chain
management, pharmacy operations, good pharmacy practice in F1 Plus BNB
outlets and other concerns, which will ensure the effective implementation of
this program.
1.7. The DOH shall pool requests for essential medicines and procure said
medicines either through the Central Office Bids and Award Committee
(COBAC) ofthe DOH or through Agency-to-Agency mode of procurement
with the PPPI to ensure adequate supply of essential medicines for the
program in the public sector, using the instruments provided in R.A. No. 9502,
such as competitive bidding, importation and when necessary the use of
Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities
for exorbitantly priced drugs which address priority diseases.
1.8. The DOH CHD and MOH-BARMM shallensure that the necessary structural
arrangements such as personnel, equipment, space and the creation of a
functional committee for coordination and monitoring are clearly identified
and established.
1.9. All Fl Plus BNB outlets nationwide shall operate only within the
responsibilities shall serve in their respective catchment areas as prescribed
by the DOH and monitored by the FDA.
1.10. Only those suppliers listed in the Philippine Government Electronic

Procurement Systems (PhilGEPS) may participate as F1 Plus BNB program
suppliers for stock replenishment of medicines.
1.11. No medicines procured under this program shall be sold to patients, to the
access sites, pharmacies or other drug establishments. The product shall bear
a marking: “Philippine Government Property-Department of Health NOT
FOR SALE”
- SPECIFIC GUIDELINES:
A. F1 Plus BNB Outlet Nomination and Licensing
The DOH shall partner with the LGUs,

regional PNP and AFP in
the provision
of support through technical assistance in pharmaceutical supply chain
management, pharmacy operations and good pharmacy practice in F1 Plus
BNB outlets shall ensure the effective implementation of this program.
Creation of a functional committee for coordination and monitoring shall be
clearly identified and established.
2. The DOH CHDs and MOH-BARMM shall conduct a preliminary assessment
of all health facilities regarding their readiness to operate a F1 Plus BNB outlets
using the Readiness Assessment Checklist (RAC).
3. The Local Chief Executive (LCE) or the head of agency shall submit to the
a
DOH CHD or MOH-BARMM letter of intent to operate a F1 Plus BNB outlet
to be submitted to the DOH Central Office for approval and budgeting.
4. All nominated F1 Plus BNB outlets shall comply with the existing licensing
guidelines of the FDA and Implementing Rules and Regulations (IRR) of
Republic Act No. 10918:
a. Secure a License to Operate (LTO):
i. For 1 to 3class municipalities (Category A), there must be a

licensed Pharmacist in each health facility. Licensed pharmacists
working in a Category A establishment/outlet may be allowed to
simultaneously work and successively render pharmacy services in
Category B_ establishments/outlets. Under this provision,
simultaneous work means that a pharmacist can be employed in
multiple establishments/outlets, provided that there is no overlap in
working time. A pharmacist shall be allowed to supervise a maximum
of four (4) establishments/outlets classified under Category B.
ii. For Category B, a certified Technical Education and Skills

Development Authority (TESDA) National Certificate (NC)- III TAs
shall be present in establishments/outlets. The licensed pharmacists in
Category B shall comply with the following:
1. Shall be physically present in the establishment/outlet for

a minimum of two (2) hours a week;
2. Location of each establishment/outlet which the licensed
pharmacist supervises shall be within the same province
per region. However, the National Capital Region
(NCR), shall be considered as a single unit;
3. The distance between the two farthest
establishments/outlets supervised by a single licensed
pharmacist shall not exceed twenty-five (25) kilometers
(km) in distance;
4, Shall be allowed to supervise a maximum of fifteen (15)
establishments/outlets; and
5. The supervising pharmacist shall likewise comply with
the other relevant requirement as may be prescribed by
the Pharmacy Board in coordination with the FDA.
Submit a Sangguniang Bayan resolution or municipal ordinance

stating the establishment of the F1 Plus BNB outlet indicating
its name and address.
The LGU shall submit a Risk Management Plan (RMP) of the

proposed F1 Plus BNB outlet.
The LGU shall pay

aregistration fee as prescribed by the FDA. The
initial registration shall be valid for two (2) years and shall be
renewable every three (3) years thereafter.
e. The LGUshall ensurethat all requirements as specified by the FDA
are completed prior to submission through the electronic portal, as
per
LTO.
FDA Circular No. 2016-004, tofacilitate the processing of
f. The DOH CHDs and MOH- BARMM shall assist the LGU in
processing the LTO.
B. F1 Plus BNB Outlet Activation
1. A Memorandum of Agreement (MOA) shall be executed between the DOH

CHDs, MOH-BARMM and LGUs, which will stipulate the roles and
responsibilities of each party in the joint implementation of the program.
The DOH CHD and MOH-BARMM shallprovide a package of selected

essential medicines based on F1 Plus BNB product portfolio (as additional
medicines) and technical assistance to the health facility to enhance their
Pharmacy services.
. All DOH and LGU procured medicines shall be placed inside the F1 Plus
BNB outlet. The LGU shall agree to the integrated pharmaceutical
management, wherein LGU medicines, vertical medicines and F1 Plus BNB
medicines are managed by the pharmacist/s assigned to
the outlet.
C. F1 Plus BNB Outlet Operation
1. The LGU - hired Pharmacist for Category A shall be responsible for

ensuring that the Fl Plus BNB is compliant with the regulatory
requirements, Good Distribution and Storage Practice (GDSP) and GPP
standards.
The F1 Plus BNB shall be expected to provide quality Pharmacy services

such as:
i. facilities and premises management;
ii. medicines supply management;
ili. dispensing of medicines and patient counselling;
iv. public health and pharmacy services such as, but not limited to:
1. Patient profiling
2. Pharmacovigilance
3. Drug therapy review; and
v. administrative and general services
The DOH CHD and MOH-BARMM, through National Drug Policy

Compliance Officers (NDPCOs) and Public Health Pharmacists (PHPs),
shall provide supportive supervision, monitoring and evaluation during
operations of the F1 Plus BNB in
accordance to DOH standards. And
D. Selection, Quantification and Forecasting of Medicines
1. Medicines to be included in the F1 Plus BNB program shall be in accordance

with Republic Act No. 9502 or the Cheaper Medicines Act which mandates
the use of the latest edition of Philippine National Formulary (PNF) as
procurement basis for government agencies.
2. The DOH shall select medicines based on the following criteria:
a. Morbidity report;
b. Hospital admission report or Identification treatment record;
c. Identified priority disease;
d. Commonly needed medicines; and
e. Submitted end-user’s Requisition and Issuance Slip (RIS)
3. The DOH shall issue a Department Memorandum for the quarterly

replenishment of stocks through the submitted RIS based on their actual
consumption and capacity to store medicines.
4. For Budgeting purposes, the DOH shall collect every March, the requests for
medicines for the succeeding year.
E. Patient Eligibility
1. The eligible patient shall complete and sign form which will be filed and
recorded in
the patient registry by the establishment/outlet.
All patients (as identified in Article 1.3 under General Guidelines) with a
valid prescription may avail of the prescribed medicines,
the F1 Plus BNB outlet.
if
available, from
Medicines shall be dispensed to patientsin complete treatment regimens for

antibiotics and one (1) month supply for maintenance medications.
F. Sourcing and Procurement
1. The acquisition of medicines shall be performed by PPPI through Agency-

to-Agency mode of procurement in accordance with R.A. No. 9184 or the
A centralized ordering agreement shall be used as deemed necessary to

assure uninterrupted pharmacy services of the F1 Plus BNB outlet.
If drug products are not locally available or with limited supply, parallel
continuousaccess for essential medicines in the F1 Plus BNB outlets.
G. Logistics Management
1. All Fl Plus BNB outlets shall manage their logistics according to the
standard procedures set by the DOH on pharmaceutical supply chain
management.
The procured medicines shall be directly delivered to the F1 Plus BNB

outlets through PPPI or an outsourced shipping agency.
All F1 Plus BNB outlets shall be compliant with Good Distribution and
Storage Practice (GDSP) in accordance with the standards adopted by the
FDA.
To ensure uninterrupted supply of medicines for all F1 Plus BNB outlets,

twenty percent (20%) of the total requested quantity of all the outlets in the
province, shall serve as the buffer stock which shall be maintained at
concerned PDOHO or MOH-BARMM warehouse.
H. Implementation and Monitoring
1. The CHD and MOH-BARMM shall

execute a MOA with
the LGU and shall
oversee the implementation in the Region through the NDPCO designates
and PHPs.
2. All CHD, MOH-BARMM and LGU procured medicines shall be placed
inside the F1 Plus BNB outlet and buffer stocks must be placed inside a
designated storage room for rational management.
The Fi Plus BNB outlets are required to submit monthly utilization,

inventory reports and patient registry to DOH-CHD, MOH-BARMM and
DOH-CO
as part of the program review, and accounting and auditing
procedures using electronic forms provided in a software being
implemented by the PD. For outlets with no access to the Internet, printed
forms shall be used, to be collected by the DOH CHDs and MOH-BARMM
through their PHPs. The PHPs shall be responsible for uploading the data
collected at the outlets without access to internet.
All inventory data as well as the RIS of all health facilities shall be quarterly
collated by PHPs and submitted to their respective CHD and MOH-
BARMM,
replenishment
toof
be forwarded to the DOH-Pharmaceutical Division for
stocks.
I. Financing
1. The DOH shall ensure sufficient and available funds for the procurement the of
essential medicines and support to operations of the F1 Plus BNB outlets.
2. The LGUs shall continue to allocate funds for medicines that are not being
supplied in the F1 Plus BNB program as part of their responsibility to provide
health services to their constituents.
J. Rational Use of Medicines and Quality Assurance
1. Only essential medicines shall be rationally selected and procured at the

national level and distributed to all identified health facilities. GDSP and
other conditions reflected on the label of drug products shall be adhered to
at all times by the Pharmacist and Technical Assistant (TA) in charge of the
©
F1 Plus BNB outlet.
The designated Pharmacist and TA shall offer full Pharmacy services to F1

Plus BNB clients including patient counseling on medicines use.
The quantity of medicines to be dispensed by the F1 Plus BNB outlet shall

be in accordance with the prescribed therapeutic regimens to a single
patient.
No F1 Plus BNB drug product shall be sold or find their way in the trade
through retail and pilferage. Civil, criminal and administrative sanctions, as
may be proper, shall be imposed following existing government policies.
The medicines delivered to the health facilities shall be subject to random

FDA
post
marketing surveillance protocols.
reported to the nearest CHDs and MOH-BARMM, while expired medicines
shall be disposed of in accordance with the Joint Department of
Environment and Natural Resources (DENR)- Department of Health (DOH)
Administrative Order No. 02, series of 2005. A witness from DOH-CHD or
MOH-BARMM, FDA and COA shall be present whenever disposal of
expired drugs is conducted.
It
ARTICLE
ROLES AND RESPONSIBILITIES
1. The DOH shall manage and oversee the implementation of the F1 Plus BNB
including its funding for medicines, logistics and human resources.
The DOH, through the PD shall develop policies and guidelines including
manual of procedures for F1 Plus BNB outlets.
The DOH shall conduct random supervisory monitoring using a harmonized

tool to analyze the implementation and compliance to the F1 Plus outlet
standards.
The Pharmaceutical Division shall provide technical assistance to the regional

counterpart on matters affecting F1 Plus BNB outlet operations.
The DOH shall employ additional PHPs and TAs to augment the shortage of
medicine management experts in local health facilities for the first three (3)
years of the implementation of the program.
B. Center for Health Development (CHD) and Ministry of Health- Bangsamoro

Autonomous Region in Muslim Mindanao (MOH-BARMM)
1. The CHD and MOH-BARMM shall oversee the implementation of the F1 Plus
BNB program at the DOH level.
The CHD Directors and MOH-BARMM Minister of Health through the

NDPCO designates shall collect, consolidate and analyze the reports coming
from the F1 Plus BNB outlets on a monthly basis.
The CHD and MOH-BARMM shall submit monthly monitoring reports to

DOH-PD on the status of the program implementation.
The CHD and MOH-BARMM shall allot augmentation fund for the advocacy,
training, monitoring and evaluation of F1 Plus BNB Program.
The CHD Director and MOH-BARMM Minister of Health and their staff shall
and resolve regional issues and other concerns needing actions on the operations
of the program
The CHD and MOH-BARMM shall enforce diligently the mechanism of stock
transfer of medicines among RHUs and HCs toprevent wastage in coordination
with the LGUs using the prescribed form. This shall be properly coordinated
with the assigned PHP and TA as well as the regional program manager.
C. Local Government Unit (LGU)
1. The LGU shall ensure proper implementation of the F1 Plus BNB Program in
its area of jurisdiction in coordination with the CHDs of MOH-BARMM, keep
and maintain prompt inventory of drug supplies and educate the communities
on rational use of medicines.
The LGU shall hire their own Pharmacists and TAs to manage the F1 Plus
BNB outlet as the DOH shall only temporarily provide the
necessary human
resource needed for the implementation of the program for the first three years.
3. The LGU shall obligate the BNB Pharmacist to have a complete inventory,
record keeping, reporting of consumption and medication needs of the
community to ensure responsive medications list.
4. The LGU shall allow the DOH assigned Public Health Pharmacist (PHP) to
conduct monitoring, inspection or audit of the F1 Plus BNB outlet as part of
program evaluation.
5. The LGU shall be responsible for improving the F1 Plus BNB Outlets by
mobilizing budget for the enhancement of pharmaceutical standards and
minimum facility requirements and likewise observe the GDSP in accordance
with FDA guidelines.
6. The Fl Plus BNB outlet shall comply with the FDA licensing requirements,
including continuing renewal of
license every three (3) years to be assisted by
the DOH CHD and MOH-BARMM.
7. The LGUs shall assist the DOH in the promotion and advocacy
BNBprogram for better implementation and utilization of the
ofthe F1 Plus
program.
8. The designated PHPs and TAs in the F1 Plus BNB

conduct full pharmacy services to their clients
outlets shall be allowed to
including patient profiling and
counseling during medicines dispensing.
ARTICLE Il
PROGRAM MONITORING
. The DOH, CHD and MOH-BARMM shall be the lead units in monitoring the
performance ofall F1 Plus BNB outlets and shall have the authority to check on their
inventory records notwithstanding and without prejudice to
a similar role that the LGU
and hospital proponent may undertake orto the regulatory functions of the FDA.
. The F1 Plus BNB outlets shall maintain the integrity and transparency of their records
and shall make such records available whenever asked by the CHD or MOH-BARMM
concerned, the DOH and other regulatory units.
- Reports on monitoring shall be submitted by the F1 Plus BNB outlets to their respective
CHDs and MOH-BARMM
HRT-PD.
on a monthly basis and shall be forwarded to the DOH-
. During implementation, a yearly evaluation of the program shall be conducted by the

PD. Three (3) years after implementation, the program shall undergo review in order to
determine whether the same shall be continued or terminated.
ARTICLE IV
IN CASE OF BREACH
In case of any breach in the provisions of this Agreement, appropriate administrative, civil
and/or criminal case/s as warranted may be instituted.
ARTICLE V
VENUE
IN CASE OF DISPUTES
In case of disputes, amicable settlement between the parties mustfirst be exhausted.
its
Should the parties be constrained to resort to court action to protect right and interest, venue
of any court action shall be laid exclusively in the proper court of the City of Manila,
Philippines.
ARTICLE VI
TERMINATION
The parties may terminate this Agreement, in whole or

in part, at any time for its convenience
if the existence of conditions is determined to cause the project implementation to be
economically, financially or technically impractical and/or necessary, such as but not limited
to fortuitous event/s or changes in law and national government policies.
This Agreement may be terminated by any party due to above stated causes by serving a Notice
of Termination at least thirty (30) days before the date of the intended termination.
ARTICLE Vil
COORDINATION
Proper coordination and facilitation activities relative to this program shall be done through
the respective Program Managers of the parties hereto:
For DOH:
DOH Center for Health Development / MOH- BARMM
Address:
Contact Number:
Email Address:
For OFFICE OF THE CITY MAYOR:
City/ Municipal Mayor
Address
Contact No(s)
10
ARTICLE
OTHER TERMS
1.Any amendment or modification hereto shall be subject to mutual agreement of the

parties in writing.
2. Neither party hereto may assign, in whole or in part, any of their respective
obligations/responsibilities without the prior written approval of the other
Vil
party.
3. If any part of this Agreement is declared unenforceable or invalid, the
remainder will continue to be valid and enforceable.
ARTICLE IX
EFFECTIVITY
This agreement shall become effective upon the signing hereof by the parties and shall remain
in effect as long as the DOH continues to provide free medicines for the program.
IN WITNESS HEREOF, the parties have signed this agreement on the date and place first
above-written.
By: DEPARTMENT OF HEALTH
DOH Center for Health Development/ OH-BARMM
By: CITY GOVERNMENT OF
City/ Municipal Mayor
SIGNED IN THE PRESENCE OF:
City Health Officer

City of
11
ACKNOWLEDGEMENT
REPUBLIC OF THE PHILIPPINES )

)S.S.
BEFORE ME, a Notary Public for this of
2019
personally appeared the following:
Name Government ID No. Date/Place Issued
Known to me and known to be the same persons who executed the foregoing instrument
and who acknowledged to me that the same are their free and voluntary acts and deeds and that
of the entities, which they respectively represent.
This instrument refers to Memorandum of Agreement consisting of twelve (12) pages,

including the page where this Acknowledgment
their instrumental witnesses.
is
written, and is signed by the parties and
IN WITNESS WHEREOF,
place above written.
I have set my hand and affixed my seal on the date and
Doc. No.
Page No.
Book No.
Series of 2019.
12
ANNEX A-2
(MOA BETWEEN DOH AND DND)
KNOW ALL MEN BY THESE PRESENTS:

2019 in by and among:
The DEPARTMENT OF HEALTH (DOR), a national government agency and existing

under the laws of the Republic of the Philippines with principal office at San Lazaro
Compound, represented by in his capacity as Secretary of Health,
and hereinafter referred to as “DOH”
-and-
The DEPARTMENT OF NATIONAL DEFENSE (DND), a national government agency

and existing under the laws of the Republic of the Philippines with principal office at Camp
General Emilio Aguinaldo, Quezon City, represented by , in his
capacity as Secretary of National Defense, and hereinafter referred to as “DND”
WITNESSETH, that
WHEREAS, the 1987 Constitution of the Philippines mandates that the State shall protect and
promote the right to health of the Filipino people and instill health consciousness among them;
integrated and comprehensive approach to health development which shall endeavor to make
essential goods, health and other social services available to all people at affordable cost;
WHEREAS, Republic Act No. 9502, otherwise known as the Universally Accessible Quality
and Cheaper Medicines Act of 2008, mandates the Department of Health (DOH) to increase
access to essential medicines for the country’s priority diseases;
WHEREAS, Republic Act No. 6675, or the Generics Act of 1988, further prescribes further
that it is the policy of the State to ensure the adequate supply of drugs and medicines with
generic names and atthe lowest possible costs;
WHEREAS, pursuant to the national program, President Rodrigo Roa Duterte pledged to
provide funds for government health programs, specifically on medicines availability under
the new Philippine Health Agenda (PHA);
WHEREAS, to
bridge the gap on access to medicines and improve the current systems the in
pharmaceutical market, the revitalization and remodeling of the “Botika ng Bayan” shall be
adopted using government instruments such as pooled procurement, parallel drug importation,
and price-volume direct negotiation with pharmaceutical manufacturers for single-source
essential medicines;
WHEREAS, the establishment of the FOURMULA Plus BOTIKA NG BAYANI (F1 Plus
1
BNBi) in Armed Forces ofthe Philippines Military Treatment Facilities (AFPMTF) or at the
point of care shall avoid additional expenses for the patients and to address other health-related
issues such as cost-effectiveness of treatment, antimicrobial resistance and adverse drug
events;
Areas);
WHEREAS, increasing government subsidy for essential medicines, for the benefit of the
poor and vulnerable population, shall reduce the patients’ high out-of-pocket (OOP) spending
on medicines, including those covered by the No-Balance Billing (NBB) program, by
preventing frequent stock outs of medicines in government health facilities;
WHEREAS, the F1 Plus BNBi program shall ensure the strict enforcement of good pharmacy
practice in all levels of health care;
WHEREAS, the DOH is now implementing a free medicines access program for vulnerable
and special populations affected by diseases which cause a significant health and economic
burden
in the country;
WHEREAS, the DND

supports the proper protection and promotion of the right to health for
all Filipino citizens;
-and-
WHEREAS, the AFPMITF, under the DND, tasked to provide health services to all active
military personnel, their dependents, and authorized civilians, was identified by the DOH to
be an F1 Plus BNBi outlet and shall be provided with F1 Plus BNBi medicines to the health
facilities free of charge;
NOW THEREFORE, forand in

consideration of the foregoing, the parties hereto have agreed
that the following terms and conditions shall be observed/implemented;
ARTICLE]
DOH AND AFPMTFs GUIDELINES FOR THE PROCESSING AND DELIVERY OF
THE MEDICINES FOR THE DOH FOURMULA
1
PLUS BOTIKA NG BAYANI (F1
PLUS BNBi) PROGRAM UNDER THE UNIVERSAL HEALTH CARE THRUST
1. GENERAL GUIDELINES:
1.1. The AFPMTFs shall work with the DOH in determining the drug needs in
relation
to specifications, quantities and allocation of essential medicines in accordance
with Executive Order No. 49, which mandates the use of the latest edition of
Philippine National Formulary as procurement basis for government procurement
agencies.
included by the said program shall be covered by PhilHealth reimbursements (for
eligible members) and/or shall be referred to foundations and other funding
institutions.
1.3. All AFPMTFs shall have pharmacies/dispensaries providing free access to

essential medicines which shall be called “DOH FOURMULA
1
Plus BOTIKA
NG BAYANI” (F1 Plus BNBi). The F1 Plus BNBi outlet shall make available
essential medicines for active military personnel and their dependents and other
authorized personnel as prescribed in Circular Nr 1 dated 20 January 2004 -
Medical/Dental Attendance and Maximum Hospitalization in AFP Health
Facilities (Annex A).
1.4. The DOH,

as the lead agency in the health sector, shall provide the overall
framework and guidance (Annex B) in the implementation of the F1 Plus
program
BNBi program, working with its Center for Health Development (CHD) or
Minister of Health-Bangsamoro Autonomous Region in Muslim Mindanao
(MOH-BARMM) for effective local implementation.
1.5. The DOH and DND shall work together in ensuring good governance
mechanisms and local accountability in the management of F1 Plus BNBi allin
AFPMTFs through compliance with the Food and Drug Administration (FDA)
regulatory requirements and DOH standards on good supply chain management.
1.6. The DOH CHD and MOH-BARMM shall initiate partnerships with AFPMTFs
and will provide support through technical assistance in supply chain
management, pharmacy operations and good pharmacy practice in F1 Plus BNBi
outlets and other concerns, which will ensure the effective implementation of this
program.
1.7. The DOH shall poolrequests for essential medicines and procure said medicines
DOH or through Agency-to-Agency mode of procurement with the PPPI to
ensure adequate supply of essential medicines for the program in the public
sector, using the instruments provided in R.A. No. 9502, such as competitive
bidding, importation and when necessary the use of Trade-Related Aspects of
Intellectual Property Rights (TRIPS) flexibilities for exorbitantly priced drugs
which address priority diseases.
1.8. The DOH CHDs and MOH-BARMM, in coordination with AFPMTFs, shall
ensure that the necessary structural arrangements such as personnel, equipment,
space and thecreation of a functional committee for coordination and monitoring
are clearly identified and established.
1.9. All F1 Plus BNBi outlets nationwide shall operate only within the responsibilities
shall serve in their respective catchment areas as prescribed by the DOH and
monitored by the FDA.
1.10. Only those suppliers listed in the Philippine Government Electronic Procurement
Systems (PhilGEPS) may participate as F1 Plus BNBi program suppliers for stock
replenishment of medicines.
1.11. No medicines procured under this program shall be sold to patients, to the access
. SPECIFIC GUIDELINES
A. F1 Plus BNBi Outlet identification
Must have an air-conditioned/well ventilated Pharmacy or Dispensary

With a Pharmacist or Technical Assistant (TA)
Regularly conducts barangay/community outreach activities
Have sufficient storage area for medicines
AVWPYNE
Compliant with Good Distribution and Storage Practices (GDSP)

Submits monthly patient registry, utilization and inventory reports
B. Licensing of F1 Plus BNBi outlets
All identified F1 Plus BNBi outlets shall comply with the existing licensing
guidelines of the FDA and shall be assisted by the DOH CHD and MOH-BARMM.
C. Selection, Quantification and Forecasting of Medicines
1. Medicines to
be included in the F1 Plus BNBi program shall be in accordance
the use of the latest edition of Philippine National Formulary as procurement
basis for government agencies.
The medicines shall be based on the following:

FPS
Morbidity report
Hospital admission report
Identified priority disease
cae Commonly needed medicines
End-user’s Requisition and Issuance Slip (RIS) — (Annex C)

disease endemic areas shall not be procured unless deemed necessary.
The medicines and quantities needed by the AFPMTFs shall be determined by

the Chief of Health Facility using the prescribed RIS (Annex C) to be provided
by the DOH.
D. Patient Eligibility
1. All patients (as identified in Article 1.3 under General Guidelines) with a valid
prescription from physicians/medical officers of AFPMTFs may avail of the
medicines, provided that he/she shall be listed to the patient registry and shall
sign the patient consent form (Annex D) for profiling.
Medicines shall be dispensedin complete treatment regimens for antibiotics and

one (1) month supply for maintenance medications
E. Sourcing and Procurement

A centralized ordering agreement shall be used as deemed necessary to assure

uninterrupted pharmacy services of the F1 Plus BNBi outlet.
continuousaccess for essential medicines in the F1 Plus BNBi outlets.
F. Logistics Management
1. All F1 Plus BNBi outlets shall manage their logistics according to the standard
procedures set by the DOH on pharmaceutical supply chain management.
The procured medicines shall be directly delivered to the AFPMTFs F1 Plus

BNBi outlets through PPPI or an outsourced shipping agency.
3. All F1 Plus BNBi outlets shall be compliant with Good Distribution and Storage
Practice (GDSPI) in accordance with the standards adopted by the FDA.
G. Implementation and Monitoring
1. The DOH CHD and MOH-BARMM shalloversee the implementation of F1

Plus BNBi program through the National Drug Policy Compliance Officer
(NDPCO) /designates and Public Health Pharmacists (PHPs) who shall be given
authority by the AFPMTFs.
The AFPMTFs are required to submit monthly utilization, inventory reports and
patient registry to DOH CHD, MOH-BARMM and DOH Central Office (DOH-
CO) as part of the program review, accounting and auditing procedures using
electronic forms provided in a software being implemented by the PD. For
to
outlets with no access the Internet, printed form shall be used, to be collected
by the DOH CHDs and MOH-BARMM through their PHPs. The PHPs shall be
responsible for uploading the data collected at the outlets without access to
internet.
All inventory data as well as the RIS of all AFPMTFs shall be quarterly collated
by PHPs, to be submitted to their respective CHD or MOH-BARMM,
forwarded to the DOH-Pharmaceutical Division for replenishment of stocks.
to be
H. Financing
1. The DOH shall ensure sufficient and available funds for the
procurement of the essential medicines and support to operations
F1 Plus BNBi outlets.
of the
2. The AFPMTFs shall continue to allocate funds for medicines that are
not being supplied in the F1 Plus BNBi program as part of their
responsibility to provide health services to their patients.

national level and distributed to all identified F1 Plus BNBi outlets. Good
dispensing/storage practice and other conditions reflected on the label of drug
products shall be adhered
the F1 Plus BNBi outlet.
to
at
all times by the Pharmacist and TA in charge of
The Pharmacist and TA designate shall offer full Pharmacy service to F1 Plus
BNBi clients including patient counseling on medicines use.
The quantity of medicines to be dispensed by the F1 Plus BNBi outlet shall be

in accordance with the prescribed therapeutic regimens to
a single patient.
No F1 Plus BNBi drug product shall be sold or find their way in the trade
through retail and pilferage. Civil, criminal and administrative sanctions as may
be proper, shall be imposed following existing government policies.
The medicines delivered to the AFPMTFs shall be subject to FDA post

marketing surveillance protocols.
reported to the nearest CHDs or MOH-BARMM, while expired medicines shall
Natural Resources (DENR)- Department of Health (DOH) Administrative
5
Order No. 02, series of 2005. A witness from DOH-CHD or MOH-BARMM,
FDA and COA shall be present whenever disposal of expired drugs is
conducted.
ARTICLE
1. The DOH shall manage the implementation of the F1 Plus BNBi including its
funding for medicines, logistics and human resources.
manual of procedures for F1 Plus BNBi outlets.

tool to analyze the implementation and compliance to the F1 Plus BNBi outlet
standards.
The DOH-PD shall provide technical assistance to the regional counterpart on

matters affecting F1 Plus BNBi operations.
The DOH-PD, through the CHDs and MOH-BARMM, shall employ additional
PHPs and TAs to augment the shortage of medicine management experts in
AFPMTFs for the first three (3) years of the implementation of the program.
B. Center for Health Development (CHD) and Ministry of Health-Bangsamoro

Autonomous Region of Muslim Mindanao (MOH-BARMM)
BNBi program at the DOH level.
The CHD and MOH-BARMM< shall manage regional warehouse and

distribution of F1 Plus BNBi commodities.
The CHD and MOH-BARMM shall manage the PHPs and TAs hired and
deployed through the Human Resources for Health (HRH) Deployment
Program.
The CHD Directors and MOH BARMM Minister of Health through the
NDPCO designates shall collect, consolidate and analyze the reports coming
from the F1 Plus BNB outlets on a monthly basis.
The CHD and MOH-BARMM shall submit monthly monitoring reports to

DOH-PD on the status of the program implementation.
training, monitoring and evaluation of F1 Plus BNBi Program.
The CHD Director MOH BARMM Minister of Health and their staff shall and
resolve regional issues and other concerns needing actions on the operations of
the program.
8. The CHD and MOH-BARMM shall enforce diligently the mechanism of stock
transfer of medicines among Rural Health Units (RHUs), Health Centers (HCs)
and AFPMTFs to prevent wastage in coordination the Local Government Units
(LGUs) using prescribed form. This shall be properly coordinated with the
assigned PHP and TA as well as well as the regional program manager.
C. Armed Forces of the Philippines Military Treatment Facilities (AFPMTFs)
1. The AFP, through the Chief of AFPMTFs, shall ensure proper implementation
of theF1 Plus BNBi Program in
its
area of jurisdiction in coordination with the
CHDs or MOH-BARMM, keep and maintain prompt inventory of drug supplies
and educate the communities on rational use of medicines.
The AFPMTFs shall ensure that their respective pharmacies have Licenses to
Operate from DOH.
They shall allow the DOH assigned PHPs to conduct monitoring, inspection or
audit of the F1 Plus BNBi outlet as part of program evaluation.
The AFP shall be responsible in improving the F1 Plus BNBi Outlets by

mobilizing budget for the enhancement of pharmaceutical standards and
minimum facility requirements and likewise observe the GDSP in accordance
with FDA guidelines.
The AFPMTFs shall assist the DOH in the promotion and advocacy of the F1
Plus BNBi program for better implementation and utilization of the program.
The designated PHPs and TAs in the F1 Plus BNB outlets shall be allowed to
conduct full pharmacy services to their clients including patient profiling and
The AFPMTFs, through their Chief Pharmacists, shall ensure efficient and
effective implementation of the program in their respective localities.
The AFPMTFs, through their Chief Pharmacists, shall quantify the needed
medicines by the population in their respective catchment areas using the
quantification tool or the RIS.
The AFPMTFs, through their Chief Pharmacists, shall ensure the following:
a. Proper storage and warehousing of the F1 Plus BNBi commodities;

b. Updates on slow/fast moving medicines, near expiry medicines and
monthly inventories to the CHDs and MOH-BARMM;
c. Submission of monthly reports to the CHDs and MOH-BARMM on
utilization and inventory, and patient registry; and
d. Coordination with the CHD and MOH-BARMM on issues and concerns
regarding the program.
ARTICLE Hl
PROGRAM MONITORING
A. The DOH, CHD and MOH-BARMM shall

be the lead units in monitoring the
performance of all
F1 Plus BNBi outlets and shall have the authority to check on their
inventory records notwithstanding and without prejudice to a similar role that the LGU
and hospital proponent may undertake or to the regulatory functions of the FDA.
B. The F1 Plus BNBi outlets shall maintain the integrity and transparency of their records
and shall make such records available whenever asked by the CHD or MOH-BARMM
concerned, the DOH and other regulatory units.
C. Reports on monitoring shall be periodically submitted by the F1 Plus BNBi outlets to

their respective CHDs or MOH-BARMM
to the DOH- HRT-PD.
on
a monthly basis and shall be forwarded
D. During implementation, a yearly evaluation of the program shall be conducted by the

ARTICLE IV
IN CASE OF BREACH
ARTICLE V
VENUE IN CASE OF DISPUTES

In case of disputes, amicable settlement between the parties must first be exhausted.
Should the parties be constrained to resort to court action to protect its right and interest, venue
Philippines.
ARTICLE VI
TERMINATION
The parties may terminate this Agreement, in whole or inpart, at any time for its convenience
ARTICLE VII
COORDINATION
For DOH:
ROLANDO ENRIQUE D DOMINGO MD, DPBO

Undersecretary of Health
Health Regulation Team
Bldg 19, San Lazaro Cmpd. Rizal Ave. cor Tayuman, Sta. Cruz, Manila
usec.ohr.doh@gmail.com
For DND:
The Surgeon General, AFP

2" F, Bulwagang Valdez, Camp General Emilio Aguinaldo, Quezon City
otsg_afp@yahoo.c
ARTICLE VIII
OTHER TERMS
1. Any amendment or modification hereto shall be subject to mutual agreement of the

parties in writing.
2. Neither party hereto may assign,

in whole or inpart, any of their obligations/
responsibilities without the prior written approval ofthe other.
3. Ifany part of this Agreement is declared unenforceable or invalid, the

remainder will continue to be valid and enforceable.
ARTICLE IX
EFFECTIVITY
This agreement shall become effective upon signing hereof by the parties and shall remain in
effect as long as the DOH continues to
provide free medicines for the program.
IN WITNESS WHEREOF, the parties have signed this Agreement on the date and place first
above-written.
By: Department of Health By: Department of National Defense
Secretary of Health Secretary of National Defense
The Chief of Staff, AFP Chief, Pharmaceutical Division
The Surgeon General Undersecretary of Health

Health Regulation Team
ACKNOWLEDGEMENT

)S.S.
BEFORE ME, a Notary Public for this of 2019

and who acknowledged to me that the same are their free and voluntary acts and deeds and that
This instrument refers to Memorandum of Agreement consisting of ten (10) pages,

including the page where this Acknowledgment is written, and is signed by the parties and
IN WITNESS WHEREOF,
Doc. No.
Page No.
Book No.
Series of 2019.
10
ANNEX A-3
(MOA BETWEEN DOH AND PNP)
KNOW ALL MEN
BY THESE PRESENTS:

2019 in by and among:
The DEPARTMENT OF HEALTH (DOR), a national government agency and existing

under the laws of the Republic of the Philippines with principal office at San Lazaro
Compound, Secretary of Health, and hereinafter referred to as “DOH”
-and-
The PHILIPPINE NATIONAL POLICE- NATIONAL CAPITAL REGION POLICE

OFFICE (PNP-NCRPO)
Republic of the
a national government agency and existing under the laws of the
Philippines with principal office at Camp Bagong Diwa, Taguig City,
represented by , in his capacity as Police Director,
and hereinafter referred to as “PNP”.
WITNESSETH, that
WHEREAS, the 1987 Constitution of the Philippines mandates that the State shall protect and
promote the right to health of the Filipino people and instill health consciousness among them;
integrated and comprehensive approach to health development which shall endeavor to make
essential goods, health and other social services available to all people at affordable cost;
WHEREAS, RA No. 9502, otherwise known as the Universally Accessible Quality and
Cheaper Medicines Act of 2008 mandating the Department of Health (DOH) to increase access
to essential medicines for the country’s priority diseases;
WHEREAS, Republic Act No. 6675, or the Generics Act of 1988, further prescribes further
that it is the policy of the State to ensure the adequate supply of drugs and medicines with
generic names andat the lowest possible costs;
WHEREAS, pursuant to the national program, President Rodrigo Roa Duterte, pledged to
provide funds for government health programs specifically on medicines availability under the
new Philippine Health Agenda (PHA);
WHEREAS, to bridge the gap on access to medicines and improve the current systems in
the
pharmaceutical market, the revitalization and remodeling of the “Botika ng Bayan” shall be
adopted using government instruments such as pooled procurement, parallel drug importation,
price-volume direct negotiation with pharmaceutical manufacturers for single-source essential
medicines;
WHEREAS, the establishment of the FOURMULA

BNBi) in the PNPor at 1 Plus BOTIKA NG BAYANI (F1 Plus
the point of care aims shall avoid additional expenses for the patients
and to address other health-related issues such as cost-effectiveness of treatment, antimicrobial
resistance and adverse drug events;
Areas);
WHEREAS, increasing government subsidy for essential medicines targeting the poor and
vulnerable population can reduce the patients’ high out-of-pocket (OOP) spending on
medicines, including those covered by the No-Balance Billing (NBB) program, by avoiding
frequent stock outs in government health facilities;
WHEREAS, the F1 Plus BNBi program shall ensure the strict enforcement of good pharmacy
practice in all levels of health care;
WHEREAS, the DOH is

now implementing a free medicines access program for vulnerable
and special populations affected by diseases which cause a significant health and economic
burden in the country;
~and-
WHEREAS, the PNP-NCRPO through its Regional Health Service (RHS) is tasked to
provide health services to all active PNP personnel and their dependents through the F1 Plus
BNBi outlet and shall be provided with the F1 Plus BNBi medicines to
the health facilities free
of charge;
NOW THEREFORE, forand

that the following
in consideration of the foregoing, the parties hereto have agreed
terms and conditions shall be observed/implemented
ARTICLE I
DOH AND PNP-NCRPO GUIDELINES FOR THE PROCESSING AND DELIVERY

OF THE MEDICINES FOR THE DOH FOURMULA
1
PLUS BOTIKA NG BAYANI
(F1 Plus BNBi) PROGRAM UNDER THE UNIVERSAL HEALTH CARE THRUST
1. GENERAL GUIDELINES:
1.1. The PNP-RHS (NCRPO) shall work with the DOH in determining the drug needs
in relation to specifications, quantities and allocation of essential medicines in
accordance with Executive Order No. 49, which mandates the use of the latest
edition of Philippine National Formulary as procurement basis for government
procurement agencies.
included by the said program shall be covered by PhilHealth reimbursements (for
eligible members) and/or referred to foundations and other funding institutions.
1.3. All Fl Plus BNBi outlets identified by PNP-RHS (NCRPO) shall have
pharmacies/dispensaries providing free access to essential medicines which shall
be called as DOH FOURMULA
1Plus BOTIKA NG BAYANI (F1 Plus BNBi).
The F1 Plus BNBi shall make available essential medicines for active PNP
personnel and their dependents.
1.4. The DOH, as the lead agency in the health sector, shall provide the overall
program framework and guidance (Annex B) in
the implementation of the F1 Plus
2
BNBi program, working with its Center for Health Development (CHD) and
Ministry of Health- Bangsamoro Autonomous Region in Muslim Mindanao
(MOH-BARMM) for effective local implementation.
1.5. The DOH and PNP-RHS (NCRPO) shall work together in ensuring good
governance mechanisms and local accountability in the management of
F1 Plus
BNBi in all PNP Health Service Facilities (PNP-HSF) through compliance with
Food and Drug Administration (FDA) regulatory requirements and DOH
standards on good supply chain management.
1.6. The DOH CHD and MOH-BARMM shall initiate partnership with PNP-RHS
(NCRPO) and will provide support through technical assistance in supply chain
management, pharmacy operations and good pharmacy practice in Fl Plus BNBi
outlets and other concerns that will ensure the effective implementation of this
program.
1.7. The DOHshall pool requests for essential medicines and procure said medicines
DOH or through Agency-to-Agency mode of procurement with the PPPI to
ensure adequate supply of essential medicines for the program in the public
sector, using the instruments provided in R.A. No. 9502, such as competitive
bidding, importation and when necessary the use of Trade-Related Aspects of
Intellectual Property Rights (TRIPS) flexibilities for exorbitantly priced drugs
which address priority diseases.
1.8. The DOH CHDs and MOH-BARMM,, in coordination with PNP-RHS (NCRPO),
shall ensure that the necessary structural arrangements such as personnel,
equipment, space and the creation of a functional committee for coordination and
monitoring are clearly identified and established.
1.9. All F1 Plus BNBi outlets nationwide shall operate only within the responsibilities
shall serve in their respective catchment areas as prescribed by the DOH and
monitored by the FDA.
1.10. Only those suppliers listed in the Philippine Government Electronic Procurement
Systems (PhilGEPS) may participate as F1 Plus BNBi program suppliers for
stock replenishment on medicines.
1.11. No medicines procured under this program shall be sold to patients, to the access
- SPECIFIC GUIDELINES:
A. F1 Plus BNBi Outlet identification
Must have an air-conditioned/well ventilated Pharmacy or Dispensary

With a Pharmacist or Technical Assistant (TA)
Regularly conducts barangay/community outreach activities
Have sufficient storage area for medicines
AMPYNS
Compliant with Good Distribution and Storage Practices (GDSP)

Submits monthly patient registry, utilization and inventory reports
B. Licensing of F1 Plus BNBi outlets
All identified F1 Plus BNBi outlets shall comply with the existing licensing
guidelines of the FDA and shall be assisted by the DOH CHD and MOH-BARMM.
C. Selection, Quantification and Forecasting of Medicines
1, Medicinesto be included in the F1 Plus BNBi program shall be in accordance

the use of the latest edition of Philippine National Formulary as procurement
basis for government agencies.
The medicines shall be based on the following:

S Morbidity report
Hospital admission report
Aor Identified priority disease
Commonly needed medicines
gS End-user’s Requisition and Issuance Slip (RIS) — (Annex B)
disease endemic areas shall not be procured unless deemed necessary.
The medicines and quantities needed by the PNP-RHS (NCRPO) shall be

determined by the Chief of RHS quarterly or as needed using the prescribed
RIS (Annex B) to be provided by the DOH.
D. Patient Eligibility
a. All patients (as identified in Article 1.3 under General Guidelines) with a valid
prescription from physicians/medical officers of PNP may avail of the
medicines provided that he/she shall be listed to the patient registry and shall
sign the patient consent form (Annex C) for profiling.
Medicines shall be dispensed in complete treatment regimens for antibiotics and

one (1) month supply for maintenance medications
E. Sourcing and Procurement

A centralized ordering agreement shall be used as deemed necessary to assure

uninterrupted pharmacy services of the F1 Plus BNBi outlet.
continuous access for essential medicines in the F1 Plus BNBi outlets.
F. Logistics Management
1. All F1 Plus BNBi outlets shall manage their logistics according to the standard
procedures set by the DOH on pharmaceutical supply chain management.
The procured medicines shall be directly delivered to the PNP-RHS (NCRPO)

F1 Plus BNBi outlets through PPPI or an outsourced shipping agency.
3. AJL F1 Plus BNBi outlets shall be
compliant with Good Distribution and Storage
Practice (GDSP) in accordance with the standards adopted by the FDA
G. Implementation and Monitoring
1. The DOH-CHD and MOH-BARMM shall

oversee the implementation of F1
Plus BNBi program through the National Drug Policy Compliance Officer
(NDPCO) /designates and Public Health Pharmacists (PHPs) who shall be given
authority by the PNP-RHS (NCRPO).
The PNP-RHS (NCRPO) are required to submit monthly utilization, inventory

reports and patient registry to DOH-CHD, MOH-BARMM and DOH Central
Office (DOH-CO) as part of the program review, accounting and auditing
procedures electronic forms provided in a software being implemented by the
PD. For outlets with no access tothe Internet, printed form shall be used, to be
collected by the DOH CHDs and MOH-BARMM through their PHPs. The
PHPs shall be responsible for uploading the data collected at the outlets without
access to internet.
All inventory data as well as the RIS of all PNP-RHS (NCRPO).

shall be quarterly collated by PHPs, to be submitted to their respective CHD
and MOH-BARMM, to be forwarded to the DOH-Pharmaceutical Division for
replenishment of stocks.
H. Financing
1, The DOH shall ensure sufficient and available funds for the
procurement of
the essential medicines and support to operations
F1 Plus BNBi outlets.
of the
The PNP-RHS shall continue to allocate funds for medicines that are not being
supplied in the F1 Plus BNBi program as part of their responsibility to provide
health services to their patients.

national level and distributed to all identified F1 Plus BNBi outlets. Good
dispensing/storage practice and other conditions reflected on the label of drug
products shall be adhered to at all times by the Pharmacist and Pharmacy
Assistant in charge of the F1 Plus BNBi outlet.
The designated Pharmacist and TA shall offer full Pharmacy service to F1 Plus
BNBi clients including
patient counseling on medicines use.
The quantity of medicines to be dispensed by the F1 Plus BNBi outlet shall be

in accordance with the prescribed therapeutic regimens to
a single patient.
No F1 Plus BNBi drug product shall be sold or find their way in the trade
through retail and pilferage. Civil, criminal and administrative sanctions as may
be proper, shall be imposed following existing government policies.
The medicines delivered to the PNP-RHS (NCRPO) may be subjected to FDA

post marketing surveillance protocols.
reported to the nearest CHDs, MOH-BARMM while expired medicines shall
5
Natural Resources (DENR)- Department of Health (DOH) Administrative
Order No. 02, series of 2005. A witness from DOH-CHD or MOH-BARMM,
FDA and COA shall be present whenever disposal of expired drugs is
conducted.
ARTICLE Il
1. The DOH shall manage the implementation of the F1 Plus BNBi including
funding for medicines, logistics and human resources.
its
manual of procedures for F1 Plus BNBi outlets.

tool to analyze the implementation and compliance to the F1 Plus BNBi outlet
standards.
The DOH-PD shall provide technical assistance to the regional counterpart on

matters affecting F1 Plus BNBi operations.
The DOH-PD, through the CHDs, and MOH-BARMM shall employ additional
PHPs and TAs to augment the shortage of medicine management experts in
PNP-RHS (NCRPO) for
the first three (3) years of the implementation of the
program.
B. Center for Health Development (CHD) and Ministry of Health- Bangsamoro

Autonomous Region in Muslim Mindanao (MOH-BARMM)
BNBi program at the DOH level.
The CHD and MOH-BARMM shall manage regional warehouse and

distribution of F1 Plus BNBi commodities.
The CHD MOH-BARMM shall manage the PHPs and TAs hired and deployed
through the Human Resources for Health (HRH) Deployment Program.
The CHD Directors and MOH-BARMM Minister of Health through the

NDPCO designates shall collect, consolidate and analyze the reports
coming from the F1 Plus BNB outlets on a monthly basis.
The CHD and MOH-BARMM shall

submit monthly monitoring reports to
DOH-PD
on the status of the program implementation.
training, monitoring and evaluation of F1 Plus BNBi Program.
The CHD Director MOH-BARMM Minister of Health and their staff shall and
resolve regional issues and other concerns needing actions on the operations
of the program.
The CHD and MOH-BARMM shall enforce diligently the mechanism of stock
transfer of medicines among Rural Health Units (RHUs), Health Centers
6
(HCs) and PNP-RHS (NCRO) toprevent wastage in coordination the Local
Government Units (LGUs) using prescribed form. This shall be properly
coordinated with the assigned PHP and TA as well as well as the regional
program manager.
C. Philippine National Police Regional Health Service (NCRPO)
l. The PNP-RHS (NCRPO) shall ensure proper implementation of the F1 Plus

BNBi Program in its area of jurisdiction in coordination with the CHDs and
MOH-BARMM, keep and maintain prompt inventory of drug supplies and
educate the communities on rational use of medicines.
The PNP-RHS (NCRPO) shall ensure that their respective pharmacies have a
License to Operate (LTO) from DOH.
. They shall allow the DOH assigned PHPs to conduct monitoring, inspection or
audit of the F1 Plus BNBi outlet as part of program evaluation.
The PNP-RHS (NCRPO) shall be responsible in improving the F1 Plus BNBi

outlets by mobilizing budget for the enhancement of pharmaceutical standards
and minimum facility requirements and likewise observe the GDSP in
accordance with FDA guidelines
They shall assist the DOH in the promotion and advocacy of the F1 Plus BNBi
program for better implementation and utilization of the program.
The designated PHPs and TAs in the F1 Plus BNB outlets shall be allowed to
conduct full pharmacy services to their clients including patient profiling and
The PNP-RHS (NCRPO) through their Chief Pharmacist, shall ensure efficient
and effective implementation of the program in their localities.
The PNP-RHS (NCRPO) through their Chief Pharmacist, shall quantify the
needed medicines by the population in their respective catchment areas using
the quantification tool or the RIS.
The PNP-RHS (NCRPO) through their Chief Pharmacist shall ensure the
following:
a. Proper storage and warehousing of the F1 Plus BNBi commodities;

b. Updates on slow/fast moving medicines, near expiry medicines and
monthly inventories to the CHDs and MOH-BARMM;
c. Submission of monthly reports to the CHDs and MOH-BARMM on
utilization and inventory, and patient registry; and
d. Coordination with the CHD and MOH-BARMM on issues and concerns
regarding the program.
ARTICLE Il
PROGRAM MONITORING
A. The DOH and its CHDs and MOH-BARMM shall be the lead units in monitoring the
performance of all
F1 Plus BNBi outlets and shall have the authority to check on their
inventory records notwithstanding and without prejudice to a similar role that the PNP
proponent may undertake or to the regulatory functions of FDA.
B. The Fl Plus BNBi outlets shall maintain the integrity and transparency of their records,
which shall be made available whenever requested by the CHD or MOH-BARMM,, the
DOH andother regulatory units.
C. Reports on monitoring shall be periodically submitted by the F1 Plus BNBi outlets to

their respective CHDs or MOH-BARMM, to be forwarded by the latter to the DOH-
HRT-PD.
D. During implementation, a yearly evaluation of the program shall be conducted by the

ARTICLE IV
IN CASE OF BREACH
ARTICLE V
VENUE IN CASE OF DISPUTES

In case of disputes, amicable settlement between the parties must first be exhausted.
Should the parties be constrained to resort to court action to protect its right and interest, venue
Philippines.
ARTICLE VI
TERMINATION
The parties may terminate this Agreement, in whole orin part, at any time for its convenience
ARTICLE VII
COORDINATION
For DOH:
Secretary of Health
FOR DOH-CHD (NCR)/ MOH-BARMM:
Regional Director / Minister of Health
For PNP (NCRPO)
Police Director
Regional Director, NCRPO
For PNP-HS:
Police Chief Superintendent

Director, Health Service
ARTICLE VIII
OTHER TERMS
1. Any amendments or modifications hereto shall be subject to mutual agreement of

the parties in writing.
2. Neither party hereto may assign in whole or in part any of their obligations/
responsibilities without the prior written approval of the other.
ARTICLE
EFFECTIVITY
This agreement shall become effective upon signing hereof by the parties and remain in effect
IX
until the DOH continues to provide free medicines for the program.
IN WITNESS HEREOF, the parties have signed this agreement on the date and place first
above-written.
By: Philippine National Police
By: PNP- Heath Service:
By: Department of Health:
By: DOH- Center for Heath Development /MOH-BARMM
Chief
Regional Heath Service, NCRPO
Chief, Pharmaceutical Division

DOH
provisions
10
ACKNOWLEDGEMENT

)S.S.
BEFORE ME, a Notary Public for this of 2018

__
and who acknowledged to me that the sameare their free and voluntary acts and deeds and that
This instrument refers to Memorandum of Agreement consisting of eleven (11) pages,

including the page where this Acknowledgment
is written, and is signed by the parties and
IN WITNESS WHEREOF,
Doc. No.
Page No.
Book No.
Series of 2019
11
FOURmula 1 + Botika ng Bayan
ANNEX B. F1+ BNB Readiness Assessment Checklist
L Assessor Information:
1 Name of Public Health Pharmacist:
2 Assigned region:
3 Contact Details:
3a Email Address:
3b Mobile number:
4 Name ofSupervising NDPCO:
IL: Site Information...

5 Complete Name Rural Health Unit (RHU):
6 Complete Address:
7 Region of RHU:
Complete name of Municipal Health Officer
8 (MHO):
9 Contact Details of Site:
9a Email Address:
9b Telephone/Mobile Number:
10 Municipality and Class:
li LGU-hired licensed pharmacist (Y/N)
12 FDA-issued LTO (Y/N)
3 Description of Site:
Illustrate the layout, identifying the following areas: Pharmacy entrance, Patient waiting area, Dispensing Area,
Storage shelves, Storage cabinets, Storage area, Compounding Area (if (if
any), Dangerous Drugs cabinet any).
Attach a separate page containing the following: itemized number and size of cabinets and shelves, and photos of
the site
“IIL Service Delivery Level:

Enumerate the average number of patients served per program per
12
month
12a Patients per program:
12b S
12c
YN
12d
12e Fr
12f
12g
12h weenranauwr
12i
12j
12k 10.
121 Total number of patients:
Iv. Remarks and Comments.

Try to assess the current state
HU rae.
of the RH no electricity, living RPh,
wvith/without Lta, Gu uncooperative,
etc.)
ANNEX C
LETTER OF INTENT
Official Letterhead of the Interested LGU
DATE
Secretary
--Or—.
Ministry of Health
Bangsamoro Autonomous Region in Muslim Mindanao (MOH-BARRM)
Dear
<< Body of the letter shall include the details of the targeted RHUs and LGUs
commitment of the F1+BNB program.
Enclosed the Sangguniang Bayan or Municipal Ordinance stating the LGUs intent to
join the program (if available) or shall commit to have once approved by the DOH.>>
Respectfully yours,
Signature over the Name of the Municipal/City Mayor

of the Philippines
Republic
REQUISITION AND ISSUANCE SLIP

1 LIST OF MEDICINES FOR THE PHILIPPINE NATIONAL POLICE (PNP) AND MILITARY HOSPITALS
|
Name
of Health
Facilities:
Region:
Complete
Address:
Antibacterials
Cefuroxime 750 vial
Ceftriaxone 1 vial
Anesthetics
Isoflurane 250 mL bottle
Sevoflurane 250 mL bottle
Bu ne (as rochloride) 0.5% 4 mL (spinal) with 8% dextrose a I
Bu ine (as rochloride) 0.5% (isobaric), 5 mL I
Am ne (as ca tablet
Losartan (as um salt) 50 tablet
as tartrate) 50 tablet
Simvastatin 20 tablet
75 tablet
Antidiabetic
Metformin (as rochloride) 500 tablet
Antibacterials
Amoxicillin (as rate) 500 capsule
Cefuroxime (as axetil) 500 tablet
as rochloride) 500 tablet
Cotrimoxazole, 800 sulfamethoxazole + 160 tablet
Co-Amoxiclav 625 tablet
as loride) 300 tablet
Metronidazole 500 tablet

NSAIDs
Celecoxib 200 capsule
Mefenamic Acid 500 tablet/
Proton Inhibitors
20 le
Solution
Oral Salts (ORS 7 sachet
Salbutamol (as sulfate) 1 mg/mL, 2.5 mL (unit dose) nebule

REQUISITION AND ISSUANCE SLIP
Immunological
25 Immunological! Anti-Tetanus Serum (Equine) 1500 vial
1U/0.7mL, 0.7 mL (IM)
6 ie fe he oe
oe fe Re oie oe oe fe fe 2c oe 2 oie oie oe ote ie oie
oe ie oie aie ake oie ae of fe ake oi oie of 2h 2 of abe ake oe oie ke 2k oie ic oe
of fe oie ake oe abe ois 2 ik fe oie oie oe ok oie
it ie fe ie 9 ik fe aie oie ik ee oo
2c ade ie ae oe ofc ode ic oe oi ok oe oie oie ok oe
ok oo a
ok oe
Requested by: Approved by:

Signature:
Name:
Designation:
Contact No.:
Email Add.:
ANNEX E
PATIENT CONSENT FORM
FOURmula Botika ng Bayan (F1* BNB)

1*
and
FOURwmula 1* Botika ng Bayani (F1* BNBi)
Patient Full Name
Attending Physician
Health Facility Name/ Address
Date
. [hereby agree, consent and/or authorize (health facility) to

access and share all my personal information — collected during my enrollment to this
program — to the DOH program administrators for the sole purpose
of program management;
I hereby attest that my enrollment and/or participation to the DOH
program is completely voluntary;
In signing this form, I certify, to the best of my knowledge, that all information I have
given — which includes my medical and financial history/status — are complete, true and
accurate;
I understand that I may be required to provide additional information and/or document(s)
to verify my financial and insurance status in order to determine my eligibility for the
aforesaid program;
I recognize and consent to the use of my personal information to determine my eligibility
to be covered by said program, as well as my required services in case of admission
hereto; and,
I assent to provide my physician all relevant information relative to my condition and
treatment, including side effect(s) of my medication.
I attest that I have read the above-written information of that the same was fully explained in a
language known to me.
Patient’s Signature: Date:
Witness Name and Signature: Date:

KASULATAN NG PAGBIBIGAY NG PAHINTULOT NG PASYENTE
Buong Pangalan ng Pasyente:
Pangunahing Manggagamot:
Pangalan ng Pasilidad Pangkalusugan:
Petsa:
. Sa pamamagitan nito, ako ay sumasang-ayon at nagbibigay pahintulot sa

(Pasilidad Pangkalusugan) na makuha ang lahat ng
impormasyon na ibinibigay ko sa taga-pamahala ng program para sa layunin ng DOH
, kung saan ako ay nais sumali.
wn
Ako ay sumasang-ayon na ang aking pagsali sa DOH ay boluntaryo.
Sa pagpirma ko nito, aking pinapatunayan na ang lahat ng impormasyon na aking
ibinigay kasama ang aking medikal at pinansyal na rekord at kasalukuyang estado ay
kumpleto, totoo at wasto sa abot ng aking kaalaman.
Aking nauunawaan na ako ay maaring makontak upang magbigay ng dagdag na
impormasyon at/o dokumento para patotohanan ang aking estadong pangpinansyal o
insyurans upang matukoy ang pagiging karapat-dapat para sa Programang
Ako ay sumasangayon na ang lahat ng impormasyon na aking ibinigay sa pag-aplay para

sa DOH ay Magagamit upang mapatotohanan at mapagdesisyunan »
kung ako ay maaring maisali sa Programa upang mabigyan ng libreng gamut.

Ako ay sumasangayon na aking ibibigay ang lahat ng nauukol na impormasyon
sa
doctor na may kinalaman sa aking kundisyon at gamutan kasama ang mga masamang
aking
epekto ng mga gamut na ibibigay ng programa.
Aking nabasa, sa wikang aking nauunawaan ang lahat ng mga impormasyon nakasaad sa itaas.
Ang nilalaman at kahulugan ng mga impormasyon ay naipaliwanag ng mabuti sa akin.
Lagda ng Pasyente: Petsa:
Lagda ng Saksi: Petsa:

ANNEX F
FOURMULA ONE PLUS BOTIKA NG BAYAN (F1+BNB) MONITORING TOOL

for the use of the Regional Pharmacist
Name of Botika ng Bayan
Address
License to Operate Number
Expiration Date
Baseline Annual Monitoring
|
Date: Date:
Yes |
No | Remarks Yes | No Remarks
A. Human Resource
1. Is there a Registered
Pharmacist in the F1+BNB?
“Uf yes, please indicate in the remarks the
name and license number
2. Is the Pharmacist officially
hired by the LGU?
3.Is the Pharmacist present
during theconduct of this
monitoring visit?
4. Is there a Pharmacy Assistant
in the FI+BNB
5. Is the PA officially hired by
the LGU?
6. Is the Pharmacist trained and
is TESDA NC III Certified?
B, Licensing
1. Is the LTO still valid?
*If no, please indicate in the remarks if they
have already applied for renewal and include
the date of application
2. Is the LTO and FI+BNB
Certificate of Compliance
present and is conspicuously
displayed inside the Pharmacy?
C. Inventory Management
1. Are inventory records
updated?
2. Does the health facility follow
the First Expiry First Out
(FEFO) and First In First Out
(FIFO) principle for supplies
with no expiry date?
3. Does the health facility
experienced stock outs?
“if yes, indicate in the remarks the list of
inedicines with stock outs
4. Does the health facility
experienced oversupply?
*if yes, indicate in the remarks the list of
medicines with oversupply
5. Are there expired medicines
in the stock now?
“if yes, indicate in the remarks the list of
expired medicines
6. Are there non-formulary
medicines in stock at the health
facility?
Building 1, San Lazaro Compound, Rizal Avenue, Sta. Cruz, 1003 Manila e Trunk Line 651-7800 local 1108, 1111, 1112, 1113
Direct Line: 711-9502; 711-9503 Fax: 743-1829 @ URL: http://www.doh.gov.ph; e-mail: ftduque@doh.gov.ph
“if yes, list down the non-formulary medicines
found during the visit.
D. Storage
1. Is the temperature monitoring
sheet updated?
2. Are medicines stored
following correct temperature
conditions?
3.Are medicines protected from
direct sunlight?
4. Generally, is there enough
space to store all medicines?
5. Is there a functioning and
well-maintained biological
refrigerator or refrigerator for
medicines?
E. OVERALL COMMENTS AND RECOMENDATIONS
Evaluation and Recommendations by: Noted by:

ss
ANNEX G. Stock Transfer Form
BotikangBayan( / )
RHU name RHU code
STOCK TRANSFER FORM
Date:
Transfer from:
Transfer to:
Stock No. Name of Medicine
Prepared by:
Signature over Printed Name of Pharmacist
Received by:
Signature over Printed Name of Pharmaci

DISPENSING AND INVENTORY REPORT FOR THE FOURMULA ONE PLUS FOR HEALTH BOTIKA NG BAYAN
(F1 Plus BNB)
Name
of Health Facility: Health Facility Classification: Name
of City/Municipal Health Officer: Contact number:
Address: Municipality: Province: Quarter:
WEST Total Menth Mont Month ont fonth Mos Month

End of Quarter
Stocks
(c) (et) (e1) {e2} 3} fi}
i {73}
(asee) —(Co+8}
Antihypertensives
Amlodipine 5mg, 30 tablets per treatment pack
Losartan 50mg, 30 tablets per treatment pack
Metoprolol 50mg, 60 tablets per treatment pack
Antidiabetic
Metformin 500mg, 90 tablets per treatment
pack
Antihypercholesterolemia
Simvastatin 20mg, 30 tablets per treatment pack
Page 1 of 3
Name of Commodity. Month (G1) fenth (G2) End of Quarter
Month Total Menth Stocks
{c3) (Q {di} acbhrey)~ (Gleb21e2}-
febedieft) te21d2+42} {As8+8) —(C+D4F)
Antibacterials
Amoxicillin (as trihydrate) 500 mg capsule

Amoxicillin 100 mg/mL, 15 mL Drops
Amoxicillin 250 mg/5 mL, 60 mL Suspension
Cefalexin 500 mg Capsule
Cefalexin 250 mg/5 mL, 60 mL Bottle
Ciprofloxacin (as hydrochloride) 500 mg tablet
Ciprofloxacin 500 mg tablet
Cloxacillin (as Sodium) 500 mg Capsule
Cotrimoxazole (Sulfamethoxazole +
Trimethoprim) 400 mg + 80mg /5 mL mg syrup
Cotrimoxazole 800 mg sulfamethoxazole + 160
mg trimethoprim tablet
Co-Amoxiclav 500 mg Amoxicillin (as trihydrate +
125 mg Potassium Clavulanate tablet
NSAIDs
Celecoxib 200 mg capsule
Mefenamic acid 250 mg capsule
Mefenamic 500 mg tablet/capsule
Proton Pump Inhibitors
Omeprazole 40 mg capsule
Page 2 of 3
Name of Commodity:
Month (G3) End of Quarter
Month Month Totat Month Month Tatat Month Month Month Total Month Month Month Total Month Month Total Stocks
{ba} (b3} (8) {ct} (c3} () (a2) {62} id3) (0) fel) lez} fe3} {2} fa) 8) 2] fAreliet} —
iGlib2re2}-
tetedtefi} (edd D12) tAtB+8) -(CoD+F}
Anti-Asthma/ Bronchodilator
Salbutamol (as sulfate) 1 mg/mL, 2.5 mL (unit
dose) nebules
Salbutamol 100 mcg/dose x 200 doses Metered
Dose Inhaler
Salbutamol 2 mg/5 mL, 60 mL syrup
Fluticasone + Salmeterol 125 mcg + 25 mcg x 120

doses Metered Dose inhaler
Fluticasone + Salmeterol 250 mcg + 25 mcg x 120
doses Metered Dose Inhaler
Topical Antibacterials
Fusidate Sodium/Fusidic Acid Ointment 2%, 5 g

Tube
Mupirocin 2%, 5 g tube
Vitamins
Vitamin B1 B6 B12 100 mg + 5 mg + 50 mcg

Tablet
Multivitamins per 5 mL, 120 mL Syrup
Antithrombotic
Clopidogrel 75 mg tablet
Provir
Page 3 of 3
of the Philippines
Republic
DISPENSING AND INVENTORY REPORT FOR THE FOURMULA ONE PLUS FOR HEALTH BOTIKA NG BAYANI (F1+ BNBi)
Name
of Health Facility: Health Facility Classification: Name of City/Municipal Health Officer: Contact number:
Address: Municipality: Province:
CU RL CLL LN
Monti
Month
(b3)
i
te
Month
{c3}
Total
Co)
Month
(a2)
Manth
(43}
Month
(ey)
Month
{e2)
(ey
jasbr eel
feledafli
Antihypertensives
Amlodipine 5mg, 30 tablets per treatment pack
Losartan 50mg, 30 tablets per treatment pack
Metoprolol 50mg, 60 tablets per treatment

pack
Antidiabetic
Metformin 500mg, 90 tablets per treatment
pack
Antihypercholesterolemia
Simvastatin 20mg, 30 tablets per treatment

pack
Antibacterials
Cefuroxime 750 mg
vial
Page 1 of 3
Ceftriaxone 1 gram vial
Name of Commodity
Month Total
{c3) ()
Anesthetics
Isoflurane 250 mL, bottle
Sevoflurane 250 mL, bottle
Bupivacaine (as hydrochloride) 0.5% 4mL with

8% dextrose, ampul
Bupivacaine (as hydrochloride) 0.5% (isobaric),
5 ml (spinal), ampul
Antibacterials
Amoxicillin (as trihydrate) 500 mg capsule
Cefuroxime (as axetil) 500 mg tablet
Ciprofloxacin (as hydrochloride) 500 mg tablet

Cotrimoxazole 800 mg sulfamethoxazole + 160
mg trimethoprim tablet
Co-Amoxiclav 500 mg Amoxicillin (as trihydrate
+ 125 mg Potassium Clavulanate tabiet
Clindamycin (as hydrochloride) 300 mg tablet
Antiprotozoal
Metronidazole 500 mg tablet
NSAIDs
Celecoxib 200 mg capsule
Mefenamic 500 mg tablet/capsule
Proton Pump inhib
Omeprazole 20 mg capsule
Name of Commodity Month
Total
Month (3)
(0)
(ci)
nti-Asthma/ Bronchodilator
Salbutamol (as sulfate) 1 mg/mL, 2.5 mL (unit

dose) nebules
Immunologicals
Anti-Tetanus Serum (Equine) 1500 IU/mL, 2.5

mi
Antithrombotic
Clopidogrel 75 mg tablet
City/Municipal
}
Healin Officer
i

DOH Administrative Order 2019-0036 Establishment of F1 Plus BNB and BNBi Program

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

DOH Administrative Order 2019-0036 Establishment of F1 Plus BNB and BNBi Program

Hochgeladen von

Copyright:

Verfügbare Formate

Republic of the Philippines

SUBJECT: Implementing Guidelines _on_ the Establishment of Fourmula One

The Botika Ng Bayan (BNB) was launched by Philippine International Trading

Cognizant of these issues on access to medicines, the Government pledged to revitalize

2. To reduce out-of-pocket expenses by providing free essential medicines to health

3. To establish partnerships with Local Chief Executives (LCEs), Medical Center

Ill. SCOPE AND COVERAGE

IV. DEFINITION OF TERMS

Geographically Isolated and Disadvantaged Areas (GIDA) - are communities

Good Pharmacy Practice (GPP) - is the practice of pharmacy provided under

National Drug Policy Compliance Officer (NDPCO) — Pharmacists under the

Department Memorandum No. 2016-0081.

Ordering Agreement — refers to a written agreement in the nature of an option

Pharmacovigilance - as the science and activities relating to detection,

10. Philippine Pharma Procurement, Inc. (PPP) — formerly known as PITC

The DOH shall pool

9. Only those suppliers listed in the Philippine Government Electronic Procurement

VI. SPECIFIC GUIDELINES

A. F1 Plus BNB and F1 Plus BNBi Outlet Nomination and Licensing

a. Secure a License to Operate (LTO):

1. Shall be physically present in the establishment/outlet

b. Submit a Sangguniang Bayan resolution or municipal ordinance stating the

B.F1 Plus BNB and F1 Plus BNBi Outlet Activation

1. A Memorandum of Agreement (MOA) shall be executed between DOH CHDs,

2. The DOH CHDs and MOH-BARMM shall

i. facilities and premises management;

D. Selection, Quantification and Forecasting of Medicines

1. Medicines to be included in the F1 Plus BNB or F1 Plus BNBi program shall be

4. Medicines that are annually provided by the DOH nationwide or to selected

2. All patients with a valid prescription from a physician or AFPMTFs/ PNP

3. Medicines shall be dispensed to patients in complete treatment regimens for

F.Sourcing and Procurement

2. A centralized ordering agreement shall be used as deemed necessary to assure

1. All Fl Plus BNB and

responsibility to provide health services to their constituents.

I. Rational Use of Medicines and Quality Assurance

VII. ROLES AND RESPONSIBILITES

A. Department of Health (DOH)

1. Pharmaceutical Division (DOH-PD)

ii. The DOH-PD through the CHDs and MOH-BARMM shall

iv. The DOH-PD shall develop policies and implementation guidelines

v. The DOH-PD shall lead the implementation of pharmacy practice

vi. The DOH-PD shall conduct random supervisory monitoring using a

vii. The DOH-PD shall provide technical assistance to the regional

. Procurement and Supply Chain Management Team (PSCMT)

i. Provide technical assistance on the supply chain management of F1

i. The DOH-COBAC shall consolidate the Project Procurement

. Disease Prevention and Control Bureau (DPCB)

i. The DOH Health Program Managers shall facilitate the inclusion of

. Centers for Health Development (CHD) and Ministry of Health-

i. The CHD and MOH-BARMM shall oversee the implementation of the

v. The CHD Directors and MOH-BARMM Minister of Health through

vi. The CHD and MOH-BARMM shall submit monthly monitoring

vii. The CHD and MOH-BARMM shall

ix. The CHD and MOH-BARMM shallenforce diligently the mechanism

12. The CHO, MHO

13. The CHO,

D. Philippine Pharma Procurement, Inc. (PPP])

4. The PPPI shall coordinate with DOH-PD regarding problems encountered on

VII. PROGRAM MONITORING AND EVALUATION

D. During implementation, a yearly evaluation of the program shall be conducted by

In case any provision of this Order, or the application thereof, is declared

(MOA BETWEEN DOH AND LGU)

KNOW ALL MEN BY THESE PRESENTS: